

CURRICULUM VITAE

Bradley Charles Martin, Pharm.D., Ph.D.

Instructional Activities: pages 3-10
Scholarly Activities: pages 11-53
Recognitions and Awards: pages 54-56
Service Activities: pages 57-63

Business Address

Department of Pharmacy Practice
University of Arkansas for Medical Sciences (UAMS)
4301 W Markham St., Slot 522
Little Rock, AR 72205-7122
BMARTIN@uams.edu
(501) 603-1992
(501) 296-1168 FAX

EDUCATION AND TRAINING

1989 - 1993	Ph.D. Pharmacy Care Administration June 1993 University of Georgia College of Pharmacy Athens, Georgia 30602
1985 - 1989	Doctor of Pharmacy June 1989 University of Illinois College of Pharmacy Chicago, Illinois 60612
1983 - 1985	Engineering and Pre-Pharmacy Curriculum University of Illinois - Chicago Chicago, Illinois 60612

ACADEMIC STATUS

Tenured Professor

ACADEMIC POSITIONS

August 2006 - Present	Professor Department of Pharmacy Practice UAMS College of Pharmacy Little Rock, AR 72205
January 2009 – June 2024	Research Associate Without Compensation HSR&D Service, Department of Veterans Affairs Little Rock, AR 72205

January 2007 – July 2017	Head, Division of Pharmaceutical Evaluation and Policy Department of Pharmacy Practice UAMS College of Pharmacy Little Rock, AR 72205
August 2004 – June 2006	Associate Professor Department of Pharmacy Practice UAMS College of Pharmacy Little Rock, AR 72205
January 2005 – Present	Adjunct Associate Professor, Department of Health Policy and Management UAMS College of Public Health Little Rock, AR 72205
Sept 2004 – Sept 2009	Adjunct Associate Professor, Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens, Georgia 30602
July 1998 - Aug. 2004	Associate Professor Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens, Georgia 30602
July 2000 - Aug. 2004	Director, Pharmacy Care Administration Graduate Program Department of Clinical and Administrative Pharmacy College of Pharmacy University of Georgia Athens, Georgia 30602
May 1993 - June 1998	Assistant Professor Department of Pharmacy Care Administration College of Pharmacy University of Georgia Athens, Georgia 30602
August 1989 - May 1993	Teaching / Research Assistant Department of Pharmacy Care Administration College of Pharmacy University of Georgia Athens, Georgia 30602

Sept. 1987 - Dec. 1987 **Teaching Assistant - Statistics**
Department of Pharmacy Administration
University of Illinois College of Pharmacy
Chicago, Illinois 60612

PROFESSIONAL EMPLOYMENT

June 1991 - July 2003 **Relief Staff Pharmacist**
Various Independent Community Pharmacies
Athens, Georgia

January 1991 - May 1993 **Staff Pharmacist**
Gilbert Health Center
University of Georgia
Athens, Georgia 30602

June 1990 - June 1994 **Staff Pharmacist**
Revco D.S, Inc.
Athens, Georgia 30605

Dec. 1985 - August 1989 **Staff Pharmacist - Pharmacy Intern**
University of Illinois Hospital
Chicago, Illinois 60612

RESIDENT INSTRUCTION AND CONTINUING EDUCATION

PROFESSIONAL PHARM.D. INSTRUCTION

Course Coordinator

Evidence Based Medicine. (PHPR 5643) 2 semester hours, undergraduate class.
Co-Course Coordinator with Dr. Jill Johnson, UAMS, 2008-2014

Pharmacy Statistics. (PHRM3210) 1 semester hour, undergraduate class.
University of Georgia, 2000-2003

Pharmaceutical Calculations. (PHM-320 / PHRM3200), 3 semester hour,
undergraduate class. University of Georgia 1997-1999

Administrative Pharmacy I. (PHM-362), 3 semester hour, undergraduate class.
University of Georgia, 1995

Pharmacy Finance. (PHR-393), 3 quarter hour, undergraduate class
University of Georgia, 1994-1995

Undergraduate Research (PHR-598/PHRM5980), An elective 1-5 hour undergraduate research elective. University of Georgia / UAMS, 1993-2004

Course Instructor

Evidence Based Medicine. (PHPR 7303) EBM, Biostatistics, and Pharmacoeconomics, 3hrs, undergraduate class. Co-Course Coordinator with Dr. Jill Johnson, UAMS, 2015-2023

Pharmacy Management. (PhPr 5733 –PhPr 7306) 3 semester hours, undergraduate class. UAMS, 2005-2023

Pharmacy Care Management. (PHM-565 / PHRM5650), 2-3 semester hour, undergraduate class. University of Georgia, 1997-2004

Pharmacy and Health Care Systems. (PHRM3750), 3 semester hour, undergraduate class. University of Georgia. 1999-2002

Problem-Based Learning. (PHRM-5140), 1 credit hour, semester, undergraduate course. University of Georgia, 1998-1999

Entrepreneurship (PHR-560), An elective 3 credit hour undergraduate class. Elective, University of Georgia, 1992

GRADUATE DIDACTIC INSTRUCTION

Course Coordinator

Applied Research Methods using Retrospective Data Sources (PHSC5343-PSGP5118) A required 3 semester hour graduate class. UAMS, 2005-2022

Pharmacoeconomics and Health Care Technology Assessment (PHSC5353-PSGP5119) A required 3 semester hour graduate class. UAMS, 2006-2023

Foundations of Pharmaceutical Evaluation and Policy Research Methods (PHSC 5323), A required 3 semester hour graduate class. UAMS, 2005-2013

Pharmaceutical Science Graduate Seminar (PHSC5041), A required 1 semester hour graduate class. UAMS, 2005-2010

Pharmaceutical Evaluation and Policy Seminar (PSGP5109) A required 1 semester hour graduate class. UAMS, 2012-2025

Pharmacoeconomics and Health Care Technology Assessment (PHRM-8670), A required 3 semester hour graduate class. University of Georgia, 2000-2004

Research Methods in Pharmacy Care Administration (PHRM-8640), A required 3 semester hour graduate class. University of Georgia, 1999-2003

Pharmacoepidemiology / Pharmacoeconomics (PHR-862), A required 4 quarter hour graduate class. University of Georgia, 1996

Health Care Systems (PHRM-8630), A required 3 semester hour graduate class. University of Georgia, 1999-2001

Health Care Systems (PHR-861), A required 4 quarter hour graduate class. University of Georgia, 1993-1997

Pharmacy Care Administration Seminar (PHRM-8620), A required 1 semester credit hour graduate seminar. University of Georgia, 1999-2003

Pharmacy Seminar (PHR-803/PHM-803), A required 1 credit hour graduate seminar. University of Georgia, 1994-1998

Special Problems in Health Promotion and Behavior (HPB-600), An elective 1 credit hour graduate class. University of Georgia, 1993-1997

Course Instructor

Foundations of Pharmaceutical Evaluation and Policy Research Methods (PSGP 5116), A required 3 semester hour graduate class. UAMS, 2015-2023

PH.D. STUDENTS - MAJOR PROFESSOR

1. **Jean-Francois Ricci** **Ph.D. conferred December 2000** - *Improving Risk Adjustment with Drug Exposure in Administrative Data.*
2. **Ron Cantrell** **Ph.D. Conferred May 2004** - *Development and Validation of Risk Assessment Models to Predict Pharmacy Expenditures for both Commercial and Medicaid Populations.*
Recipient of The Managed Care Pharmacy Fellowship:
Sponsored by Athens Area Health Plan Select; 1998-00,
Recipient of a University Wide Assistantship, 2001-2002.
3. **Sandhya Pannicker** **Ph.D. Conferred December 2004** - *Impact of Anti-Allergic Medication on Asthma Incidence Cost and Exploratory Analysis of for Risk Factors for Asthma.*

Recipient of an Internship sponsored by GlaxoSmithKline 2000. Recipient of The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 2001.

4. **Rahul Ganguly** **Ph.D. Conferred May 2003** - *Antipsychotic Polypharmacy vs. Monotherapy in the Treatment of Schizophrenia*. Nominated to Represent the University of Georgia in the 2003 Council of Graduate Schools (CGS) / UMI Distinguished Dissertation Award Competition in Biological and Life Sciences (Peer reviewed nomination where only best at UGA is forwarded to national competition)
5. **Dayin Koompalum** **Ph.D. Conferred August 2004** - *The Risk Benefit Profile of Non-Steroidal Anti-Inflammatory Drugs (NSAIDS) as Chemopreventives*. Recipient of a Thailand Government Sponsored Fellowship and was awarded a scholarship to attend the 1st International Conference on Therapeutic Risk Management & 19th International Conference on Pharmacoepidemiology
6. **Hua Chen** **Ph.D. Conferred August 2005** - *The economic and clinical impacts of prescribing antidepressant, anticonvulsant and antipsychotic medications off-label for patients with anxiety, depression, bipolar disorder or schizophrenia*. Recipient of a University Wide Assistantship 2000 - 2003. GlaxoSmithKline Summer Internship 2004
7. **Anand Shewale** **Ph.D. conferred December 2016** - *Comparative effectiveness of Hyaluronic acid injections for delay of surgical interventions among patients with knee osteoarthritis*. Recipient of the ACHI Health Policy Fellowship 2014-2015
8. **Anuj Shah** **Ph.D. conferred December 2018** - *Impact of Medicaid Expansion on Inpatient, ED and Substance Use Disorder Treatment Utilization and the Potential Impacts of Limited Medicaid Expansion*. Recipient of the ACHI Health Policy Fellowship 2016-2017
9. **Corey Hayes** **Ph.D. conferred December 2018** - *The Impact of Discontinuation and Opioid Dose Changes on Pain and Opioid Adverse Events*. Recipient of the 2107 AFPE Fellowship and NIDA R36DA046717 Dissertation Award

9. **Xiaocong Li** **Ph.D. conferred December 2018** - *Developing and Validating Opioid Risk Prediction Tools among Privately Insured Prescription Opioid Users*
Opioid risk prediction tool commercialized to TrestleTree LLC
10. **Divyan Chopra** **Ph.D. conferred December 2020** - *Social Network Analysis of Provider Networks in Arkansas for Management of Pain*
10. **Mahip Acharya** **Ph.D. conferred May 2022** - *Opioid trajectories, safety and potential opioid misuse among individuals with tramadol, short-acting hydrocodone and short-acting oxycodone therapy.*
Finalist (Top 3) for the 2020 Tufts-Center for the Evaluation of Value and Risk in Health Cost-Effectiveness Analysis Paper of the Year Award
11. **Nahed Elhassan** **Ph.D. anticipated Fall 2025**
12. **Allen Smith** **Ph.D. anticipated Summer 2025**
Poster selected for ISPOR Spotlight presentation and finalist for poster award.
NIDA T32 Postdoctoral Fellow
13. **Ruston Koonce** **Ph.D. anticipated Fall 2025**
NIDA T32 Postdoctoral Fellow

PH.D. STUDENT DISSERTATIONS ADVISORY COMMITTEE

1. **Joey Crosby** **Ph.D. received Spring 1995** - *A BiPhasic Analysis of Medicaid Emergency Room Utilization about a Prescription Drug Constraint.*
2. **Raul Arocho** **Ph.D. received Spring 1995** - *Validation of the USA-Spanish Version of the SF-36 in the Cuban American Population.*
3. **Christopher Cook** **Ph.D. received Spring 2002** - *Validation of the Transtheoretical Model in Medication Compliance Behavior.*
4. **Melanie Provost** **Ph.D. received Summer 2004** – *The Impact of E-health Information on Patient Medication Adherence, Attitudes, and Knowledge.*

5. **Niranjan Kathe** **Ph.D. conferred May 2019** – *Impact of Medicaid Expansion on Inpatient, ED and Substance Use Disorder Treatment Utilization and the Potential Impacts of Limited Medicaid Expansion*
6. **Mrinmayee Lakkad** **Ph.D. conferred May 2022** - *Factors associated with guideline-concordant pharmacological treatment for neuropathic pain among breast cancer survivors*
7. **Ruchira Mahashabde** **Ph.D. conferred August 2023** - *Immune check point inhibitors use in non-small cell lung cancer patients 65 years or older with synchronous brain metastases*
8. **Filmon Wolde** **Ph.D. Anticipated Spring 2025**

M.S. STUDENT - MAJOR PROFESSOR

- 1 **Laura Gressler** **M.S. conferred Summer 2017;**
Prescribing trends and the effect of concomitant use of benzodiazepines and opioids on the risk of adverse outcomes in an opioid prescribed Veteran population
2. **Kayleigh Majercak** **M.S. conferred Fall 2014;**
Use Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) And Risks Of Breast And Endometrial Cancer Among Postmenopausal Women: A Plco Study
3. **Josh Brown** **M.S. conferred Fall 2014;**
Comparison of inappropriate prescribing criteria for the elderly – Beers 2003, Beers 2012, and STOPP Criteria
4. **Anand Shewale** **M.S. conferred Summer 2014;**
Comparison Of Atrial Fibrillation Decision Support Tools And Guidelines Used To Guide Anticoagulation Therapy For Patients With Nonvalvular Atrial Fibrillation
5. **Mir Ali** **M.S. conferred Summer 2014**
The Use of Montelukast and Neuropsychiatric Events among Pediatrics with Asthma: A Nested Case-Control Study
6. **Pravin Patil** **M.S. conferred Spring 2013**
A Descriptive Study Of Opioid Use In The Management Of Diabetic Peripheral Neuropathy (DPN) In A Large Commercially Insured Population

7. **Mugdha Gokhale** **M.S. conferred Summer 2011;**
Prescription Acquired Acetaminophen Use and Risk Hepatotoxicity, Nephrotoxicity and Asthma: A Case Control Study
8. **Kejal Parikh** **M.S. conferred Fall 2008;**
Impact of an Inhaled Corticosteroid Preferred Drug List Policy on Utilization, Costs, Adherence, and Persistence in Arkansas Medicaid Enrollees
9. **Sudeep Karve** **M.S. conferred Summer 2007;**
Comparing the Predictive Validity of 8 Adherence Measures Using Administrative Data
10. **Robert C. Conrad** **M.S. conferred Summer 2007; Thesis Title –**
Impact of 3-tier Prescription Copayment Implementation on Prescription Discontinuation and Switching Behavior of Military Beneficiaries. Inflammatory Drug Exposure and the Association with
11. **Tim Niecko** **M.S. conferred Fall 2001;**
A Pharmacoepidemiologic Assessment of Nonsteroidal Anti Inflammatory Drug Exposure and the Association with Colorectal Cancer, Gastrointestinal and Renal Adverse Events
Recipient of the S.O.S. Summer Internship, 1998
12. **Jayanti Nerurkar** **M.S. conferred Fall 2001; Thesis Title -** *Costs Per Death Averted with Venous Thromboembolism Prophylaxis in Patients Undergoing Knee Arthroplasty/Replacement*

M.S. STUDENT THESES ADVISORY COMMITTEE

1. **Ryan Sanders** **M.S. conferred Fall 2019; University of Arkansas School of Engineering; *Extracting Patterns in Medical Claims Data for Predicting Opioid Overdose***
1. **Pravin Potukuchi** **M.S. Conferred Summer 2014; *Association of Urinary Incontinence and its Treatment Patterns with Comorbid Conditions***
3. **Sharvari Bhurke** **M.S. Conferred Fall 2011; *The Effect of Interaction Between Clopidogrel and Proton Pump Inhibitors on Adverse Cardiovascular Outcomes in Patients with Acute Coronary Syndrome***
4. **Amol Dahamne** **M.S. Conferred Fall 2009; *Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics***
5. **Prathamesh Pathak** **M.S. Conferred Summer 2007; Thesis Title - *An Investigation of Evidence-Based Versus Non Evidence-Based Off-Label Use of Atypical Antipsychotics in Arkansas Medicaid Pediatric Population: 2001-2005***
6. **Reshma Banavali** **Masters Thesis Defended Spring 2001; Thesis Title - *The Influence of Direct to Consumer Advertising on physician Visit Rates.***
7. **Vijay Nadipelli** **Masters Thesis Defended Summer 1995; Thesis Title – *Job Satisfaction of Community Pharmacy Technicians.***
8. **Anu A Krishnan** **University of North Carolina, College of Pharmacy; **Ex-officio committee member****

VISITING AND GUEST LECTURES

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Short Course

- | | |
|-------------|---|
| 2007 - 2019 | “Instrumental Variables in Addressing Selection Bias in Observational Studies” Instructor with Benjamin Craig, Ph.D., and Antoine Elkhoury, Ph.D. |
| 2012 - 2022 | “Introduction to Retrospective Database Analysis” |

SCHOLARLY ACTIVITIES

CHAPTERS IN BOOKS

1. Fischbach L and **Martin BC** (2014). Cohort and Case Control Studies in Principles of Research Design and Drug Literature Evaluation. ed. Aparasu RR, Sherer JT, Bentley JP. Jones & Bartlett. Burlington, MA
2. **Martin BC** (2011). Secondary Data Analysis: Administrative Data in Research Methods for Pharmaceutical Practice and Policy. ed. Rajender R. Aparasu. Pharmaceutical Press, London, UK: 203-226.
3. **Martin BC** et al. (2010) An abridged Checklist for Evaluation of Research from Retrospective Databases in Analysis of Observational Health-Care Data Using SAS, ed. Douglas Fairies. SAS Institute, Cary, NC. 287-294.
4. **Martin BC**, Pathak DS, Kwon JW, Batenhorst AS, Sharfman M. (2003) "Assessment of the responsiveness of the Migraine-Specific Quality of Life Questionnaire (version 2.1)" in Reducing the Burden of Headache, eds. Olesen J, Steiner TJ, Lipton RB. Oxford University Press Inc, New York, USA: 116-120.
5. **Martin BC**, Pritchard FL, Kotzan JA, Perri M, Sclar DA. (1999) "Case Studies in Pharmacoeconomics and Assessment of Outcomes" in Pharmacoeconomics and Outcome Assessment - A Global Issue ed. Sam Salek, Euromed Communications Ltd. Haslemere, Surrey, England: 53-72.

REFEREED ORIGINAL RESEARCH JOURNAL PUBLICATIONS

(all have undergone significant editorial review)

*denotes articles in which I was the senior corresponding author and/or the faculty supervisor for graduate student research

1. *ElHassan NO, Farnam C, Thompson JW, Stanley N, Hayes CJ, Li C, Mourani PM, Hudson TJ, McGehee R, **Martin BC**. From card to cradle: examining medical cannabis purchasing among pregnant women in Arkansas. AJOG MFM, epub ahead of print. PMID: 41317990.
2. Ararat E, Rastogi D, **Martin BC**. Metformin use is associated with reduced systemic steroid courses among pediatric asthma patients with diabetes or elevated blood glucose levels. Respir Med. 2025 Nov;248:108403. Epub 2025 Oct 6. PMID: 41061902; PMCID: PMC12551444.
3. Mahashabde RV, Bhatti SA, **Martin BC**, Painter JT, Patel M, Rodriguez A, Ying J, Li C. Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain Metastasis. Curr Oncol. 2025 Sep 5;32(9):499. PMID: 41002569; PMCID: PMC12468429.

4. Vyas V, Fuccello A, Corbin SL, **Martin BC**, Schootman M, Mavros MN. Venous thromboembolism diagnosis definition in claims data: implications for research. J Thromb Thrombolysis. 2025 Jun 22. Epub ahead of print. PMID: 40544387.
5. Vizza L, Maher CG, Ivers R, McLachlan AJ, Kelly PJ, Blyth F, Clare PJ, Thompson R, Lung T, Degenhardt L, Reid S, **Martin BC**, Wright M, Osman R, French SD, McCaffery KJ, Campbell G, Jenkins HJ, Mathieson S, Boogs M, McMaugh J, Bennett C, Stanaway F, Abdel Shaheed C. (2025) Evaluating the effect of incentives on recruiting people with low back pain with limited English proficiency as part of the COMFORT cluster randomised controlled trial: a study protocol for a study within a trial (SWAT). Trials. 2025 Jun 17;26(1):209. PMID: 40528191; PMCID: PMC12175361.
6. Corbin SL, Harris L, Fuccello A, Laryea J, Schootman M, **Martin BC**, Mavros MN. (2025) Clinical outcomes of extended venous thromboembolism prophylaxis after oncologic colorectal surgery. J Gastrointest Surg. 2025 May;29(5):102018. Epub 2025 Mar 12. PMID: 40086587.
7. Dong K, Fuccello A, Schootman M, **Martin BC**, Mavros MN. (2025) Disparities in Extended Venous Thromboembolism Prophylaxis After Pancreatic Cancer Surgery. Ann Surg Oncol. 2025 Sep;32(9):6541-6549. Epub 2025 May 24. PMID: 40413324.
8. Dong K, Fuccello A, Schootman M, **Martin BC**, Mavros MN. Venous thromboembolism following oncologic pancreas and liver surgery. HPB (Oxford). (2025) Oct 31:S1365-182X(25)01673-9. Epub ahead of print. PMID: 41353052; PMCID: PMC12700433.
9. Lazic A, Thomsen MR, Brown CC, **Martin BC**, Goudie A, Thompson JW. (2025) The relationship between aging out of the special supplemental nutrition program for women, infants, and children assistance and weight status in kindergarten. Prev Med Rep. 2025 May 29;55:103125. PMID: 40521016; PMCID: PMC12166866.
10. *Porter A, Smith AM, Gokarakonda SB, Wilson MP, **Martin BC**. (2025) Empty bottles, rising risks: A case-crossover study on psychotherapeutic medication depletion and suicide triggers. J Affect Disord. 2025 Apr 1;374:579-586. Epub 2025 Jan 17. PMID: 39828024.
11. J Hayes C, Bin Noor N, Raciborski RA, **Martin BC**, J Gordon A, J Hoggatt K, Hudson T, A Cucciare M. (2025) Development and validation of machine-learning algorithms predicting retention, overdoses, and all-cause mortality among US military veterans treated with buprenorphine for opioid use disorder. J Addict Dis. 2025 Jul-Sep;43(3):207-224. Epub 2024 Jun 30. PMID: 38946144.
12. **Martin BC**, Thompson JW, Goudie A, Farnam C, Noori K, Stanley N, Daniels JR, Hudson TJ. (2024) A Statewide Examination of Medical Cannabis Purchasing Patterns in Arkansas Over the Three Years Immediately Following Legalization. Cannabis Cannabinoid Res. 2024 Sep 23. Epub ahead of print. PMID: 39311804.
13. *Smith AM, Shah A, **Martin BC**. (2024) An updated view on the influence of initial opioid prescription characteristics on long-term opioid use among opioid naïve patients. Drug Alcohol Depend. 2024 Dec 1;265:112463. Epub 2024 Oct 24. PMID: 39549364.

14. *Smith AM, Peng C, Porter A, **Martin BC**. (2024) The role of prescribed controlled substance acquisition as potential triggers of opioid overdose: A case-crossover study. Int J Drug Policy. 2024 Dec;134:104620. PMID: 39432978.
15. Mahashabde RV, Bhatti SA, **Martin BC**, Painter JT, Rodriguez A, Ying J, Li C. (2024) Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases. Transl Lung Cancer Res. 2024 Jul 30;13(7):1620-1634. PMID: 39118898
16. Hayes CJ, **Martin BC**, Hoggatt KJ, Cucciare MA, Hudson TJ, Gordon AJ. (2024) Average Daily Dose Trajectories for Episodes of Buprenorphine Treatment for Opioid Use Disorder. Subst Use Addictn J. 2024 Oct;45(4):727-735. PMID: 39068539.
17. Hayes CJ, Raciborski RA, **Martin BC**, Gordon AJ, Hudson TJ, Brown CC, Pro G, Cucciare MA. (2024) Are gaps in rates of retention on buprenorphine for treatment of opioid use disorder closing among veterans across different races and ethnicities? A retrospective cohort study. J Subst Use Addict Treat. 2024 Nov;166:209461. PMID: 39067770.
18. *Acharya M, Hayes CJ, Li C, Painter JT, Dayer L, **Martin BC**. (2024) Opioid therapy trajectories of patients with chronic non-cancer pain over 1 year of follow-up after initiation of short-acting opioid formulations. Pain Med. 2024 Mar 1;25(3):173-186. PMID: 38243702.
19. *Koonce RM, **Martin BC**. (2024) The association between suspected long-COVID and stimulant prescribing in the United States. Psychiatry Res. 2024 Jan;331:115686. PMID: 38142603.
20. Shaheed AC, Ivers R, Vizza L, McLachlan A, Kelly PJ, Blyth F, Stanaway F, Clare PJ, Thompson R, Lung T, Degenhardt L, Reid S, **Martin B**, Wright M, Osman R, French S, McCaffery K, Campbell G, Jenkins H, Mathieson S, Boogs M, McMaugh J, Bennett C, Maher C. (2023) Clinical Observation, Management and Function Of low back pain Relief Therapies (COMFORT): A cluster randomised controlled trial protocol. BMJ Open. 2023 Nov 21;13(11):e075286. PMID: 37989377.
21. Lakkad M, **Martin B**, Li C, Harrington S, Dayer L, Painter JT. (2023) The use of gabapentinoids and opioids and risk of developing opioid-induced respiratory depression among older breast cancer survivors with neuropathic pain. J Cancer Surviv. 2023 Feb 8. Epub ahead of print. PMID: 36753003.
22. *Smith AM, Acharya M, Hudson T, Hayes C, Porter A, Turpin J, Bona J, Utecht J, **Martin BC**. (2023) Evaluating the temporal association between the recency of prescribed controlled substance acquisition and fatal and non-fatal opioid overdose. J Am Pharm Assoc (2003). 2023 Mar-Apr;63(2):648-654.e3. PMID: 36628659.
23. Mavros MN, Johnson LA, Schootman M, Orcutt ST, Peng C, **Martin BC**. (2023) Adherence to Extended Venous Thromboembolism Prophylaxis and Outcomes After Complex

- Gastrointestinal Oncologic Surgery. Ann Surg Oncol. 2023 Sep;30(9):5522-5531. Epub 2023 Jun 20. PMID: 37338748.
24. Jain N, **Martin BC**, Dai J, Phadnis MA, Al-Hindi L, Shireman TI, Hedayati SS, Rasu RS, Mehta JL. (2023) Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. Kidney360. 2022 May 18;3(8):1374-1383. PMID: 36176642.
 25. Mahashabde R, Bhatti SA, **Martin BC**, Painter JT, Rodriguez A, Ying J, Li C. (2023) Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases. JCO Oncol Pract. 2023 Sep 20:OP2300042. Epub ahead of print. PMID: 37729600.
 26. *Acharya M, Hayes CJ, Li C, Painter JT, Dayer L, **Martin BC**. (2023) Comparative Study of Opioid Initiation With Tramadol, Short-acting Hydrocodone, or Short-acting Oxycodone on Opioid-related Adverse Outcomes Among Chronic Noncancer Pain Patients. Clin J Pain. 2023 Mar 1;39(3):107-118. PMID: 36728675.
 27. Lakkad M, **Martin BC**, Li C, Harrington S, Dayer L, Painter JT. (2023) Healthcare costs and utilization associated with pain among breast cancer survivors: a propensity score matched cohort study using SEER-Medicare data. J Cancer Surviv. 2023 Aug;17(4):917-950. Epub 2022 Nov 12. PMID: 36369622.
 28. Mahashabde RV, Shrikhande MA, Han X, **Martin BC**, ElHassan NO, Hayes CJ. (2023) Concordance of Opioid Exposure in All Payers Claims Database with Prescription Drug Monitoring Program Database Using Arkansas as a Case Example. Health Serv Res. 2023 Aug;58(4):938-947. PMID: 36519709.
 29. *Acharya M, Hayes CJ, Li C, Painter JT, Dayer L, **Martin BC**. (2022) Development of a potential opioid misuse measure from administrative dispensing data and contrasting opioid misuse among individuals on long-term tramadol, long-term short-acting hydrocodone or long-term short-acting oxycodone therapy in Arkansas. Curr Med Res Opin. 2022 Nov;38(11):1947-1957. PMID: 36000252.
 30. *Hayes CJ, Koonce RM, Gressler LE, Hu B, Williams JS, **Martin BC**. (2022) Association between opioid therapy trajectories and potential opioid-related adverse health events. Pharmacoepidemiol Drug Saf. 2022 Oct;31(10):1075-1090. PMID: 35695189.
 31. *Acharya M, Chopra D, Smith AM, Fritz JM, **Martin BC**. (2022) Associations Between Early Chiropractic Care and Physical Therapy on Subsequent Opioid Use Among Persons With Low Back Pain in Arkansas. J Chiropr Med. 2022 Jun; 21(2): 67-76. PMID: 35774633; PMCID: PMC9237579
 32. Jain N, **Martin BC**, Dai J, Phadnis MA, Al-Hindi L, Shireman TI, Hedayati SS, Rasu RS, Mehta JL. (2022) Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. Kidney360. 2022 May 18;3(8):1374-1383. PMID: 36176642; PMCID: PMC9416835.

33. Jain N, Phadnis MA, **Martin BC**, Mehta JL. (2022) Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. Am J Cardiol. 2022 Jan 1;162:209-211. PMID: 34740395
34. *Hayes CJ, Krebs EE, Brown J, Li C, Hudson T, **Martin BC**. (2022) Impact of transitioning from long-term to intermittent opioid therapy on the development of opioid-related adverse outcomes: A retrospective cohort study. Drug Alcohol Depend. 2022 Feb 1; 231:109236.. PMID: 34974270.
35. *Acharya M, Zorn KK, Simonson ME, Bimali M, Moore GW, Peng C, **Martin BC**. (2022) Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013–2018. Hereditary Cancer in Clinical Practice, 2022 Dec; 20 (1): 1-11.
36. *Hayes CJ, Krebs EE, Li C, Brown J, Hudson T, **Martin BC**. (2022) Association between Discontinuing Chronic Opioid Therapy and Newly Diagnosed Substance Use Disorders, Accidents, Self-Inflicted Injuries and Drug Overdoses within the Prescribers' Health Care System: A Retrospective Cohort Study. Addiction. 2022 Apr;117(4):946-968. PMID: 34514677.
37. *Chopra D, Li C, Painter JT, Bona JP, Nookaew I, **Martin BC**. (2021) Characteristics and Network Influence of Providers Involved in the Treatment of Patients with Chronic Back, Neck or Joint Pain in Arkansas. J Pain. 2021 Jun 24: S1526-5900 00246-7 (21) Epub ahead of print. PMID: 34174385.
38. *Hayes CJ, Krebs EE, Brown J, Li C, Hudson T, **Martin BC**. (2021) Association Between Pain Intensity and Discontinuing Opioid Therapy or Transitioning to Intermittent Opioid Therapy After Initial Long-Term Opioid Therapy: A Retrospective Cohort Study. J Pain. 2021 Jun 27:S1526-5900(21)00248-0. Epub ahead of print. PMID: 34186177.
39. *Hayes CJ, Gressler LE, Hu B, Jones BL, Williams JS, **Martin BC**. (2021) Trajectories of Opioid Coverage After Long-Term Opioid Therapy Initiation Among a National Cohort of US Veterans. J Pain Res. 2021 Jun 14;14:1745-1762. PMID: 34163232.
40. *Chopra D, Li C, Painter JT, Bona JP, Nookaew I, **Martin BC**. (2021) A Social Network Analysis of Provider Networks Leading to Opioid Initiation Among US Adults. Glob J Anes & Pain Med 4(3)-2021. GJAPM.MS.ID.000187. DOI: 10.32474/GJAPM.2021.04.000187
41. Teeter BS, Jensen CR, Thomas JL, **Martin BC**, McElfish PA, Mosley CL, Curran GM. (2021) Perceptions of HPV vaccination and pharmacist-physician collaboration models to improve HPV vaccination rates, Exploratory Research in Clinical and Social Pharmacy. 2021; Volume 2: 100014.
42. Teeter BS, Thannisch MM, **Martin BC**, Zaller ND, Jones D, Mosley CL, Curran GM. (2021) Opioid overdose counseling and prescribing of naloxone in rural community pharmacies: A pilot study. Exploratory Research in Clinical and Social Pharmacy. June, 2021; 2: 100019.

43. *Hayes CJ, Krebs EE, Hudson T, Brown J, Li C, **Martin BC**. (2020) Impact of Opioid Dose Escalation on Pain Intensity: A Retrospective Cohort Study. Pain. 2020 May;161(5):979-988. PMID: 31917775
44. *Hayes CJ, Krebs EE, Hudson T, Brown J, Li C, **Martin BC**. (2020) Impact of Opioid Dose Escalation on the Development of Substance Use Disorders, Accidents, Self-Inflicted Injuries, Opioid Overdoses, and Alcohol and Non-Opioid Drug-Related Overdoses: A Retrospective Cohort Study. Addiction. 2020 Jun;115(6):1098-1112. PMID: 31944486.
45. *Acharya M, Chopra D, Hayes C, Teeter B, **Martin BC**. (2020) Cost-Effectiveness of intranasal naloxone distribution to high-risk prescription opioid users. Value in Health. 2020 Apr;23(4):451-460. PMID: 32327162.
46. Goudie A, **Martin BC**, Li C, Lewis L, Han X, Kathe N, Wilson JC, Thompson J. (2020) Higher Rates of Preventive Health Care With Commercial Insurance Compared With Medicaid: Findings From the Arkansas Health Care Independence" Private Option" Program. Medical Care 2020 Feb;58(2):120-127. PMID: 31702590.
47. *Shah A, Hayes CJ, Lakkad M, **Martin BC**. (2019) Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use, and High-risk Opioid Use. J Gen Intern Med. 2019 Aug;34(8):1419-1426. PMID: 30684198.
48. Teeter BS, Mosley C, Thomas JL, **Martin B**, Jones D, Romero JR, Curran GM. (2020) Improving HPV vaccination using implementation strategies in community pharmacies: Pilot study protocol. Res Social Adm Pharm. 2020 Mar;16(3):336-341. PMID: 31174950.
49. Freeman PR, Curran GM, Drummond KL, **Martin BC**, Teeter BS, Bradley K, Schoenberg N, Edlund MJ. (2019) Utilization of prescription drug monitoring programs for prescribing and dispensing decisions: Results from a multi-site qualitative study. Res Social Adm Pharm. 2019 Jun;15(6):754-760. PMID: 30243575
50. Curran GM, Freeman PR, **Martin BC**, Teeter BS, Drummond KL, Bradley K, Thannisch MM, Mosley CL, Schoenberg N, Edlund M. (2018) Communication between pharmacists and primary care physicians in the midst of a U.S. opioid crisis. Res Social Adm Pharm (18); 2018; S1551-7411. PMID: 30170901.
51. *Brown C, Nevola A, **Martin BC**. (2018) Lack of Impact of the 2009 USPSTF Guidelines on Rates of Mammography Screening. J Womens Health (Larchmt). 2018 Jul;27(7):875-884. PubMed PMID: 29583065; PMCID: PMC6065518.
52. Heldenbrand SD, Dayer LE, **Martin BC**, O'Brien C, Choi AN, Gubbins PO, Hawthorne J, Ramey M, Willis K, Flowers SK. (2018) APPE Evaluations are Positively Associated with MMI, Pre-pharmacy GPA and Pharmacy GPA. Am J Pharm Educ. 2018 Sep;82(7):6326. PubMed PMID: 30323388; PubMed Central PMCID: PMC6181167.

53. Kashyap A, **Martin BC**, Mittal D, Li C. (2018) Metabolic adverse events associated with antipsychotic polypharmacy versus monotherapy among new pediatric users. (2018) A Epidemiol Public Health. May 2018; 1: 1003
54. Hudson TJ, Painter JT, Gressler LE, Lu L, Williams JS, Booth BM, **Martin BC**, Sullivan MD, Edlund MJ. (2018) Factors Associated with Opioid Initiation in OEF/OIF/OND Veterans with Traumatic Brain Injury. Pain Med; 2018 Apr 1;19(4):774-787 PubMed PMID: 29036680.
55. Matthews EE, Li C, Long CR, Narcisse JM, **Martin BC**, Mcelfish PA. (2018) Sleep Deficiency among Native Hawaiian/Pacific Islander, Black, and White Americans and the Association with Cardiometabolic Diseases: Analysis of the National Health Interview Survey Data. (2018) Sleep Health;4(3):273-283. PMID: 29776622.
56. LE Gressler, **BC Martin**, TJ Hudson, JT Painter. (2018) Relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans. Pain. 2018;159(3):451-459. PubMed PMID: 29189516.
57. Singh M, Raghavan D, Williams JS, **Martin BC**, Hudson TJ, Owen RR, Jain N. Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans. Am J Nephrol. 2018;47(2):67-71. PubMed PMID: 29393120; PMCID: PMC5969069.
58. * Shah A, Hayes CJ, **Martin BC**. (2018) Factors Influencing Long-Term Opioid Use Among Opioid Naïve Patients: an Examination Of Initial Prescription Characteristics and Pain Etiologies. The Journal of Pain, 18 (11), 1374-1383. PMID: 28711636
59. *Shah A, Hayes CJ, **Martin BC**. (2017) Characteristics of the Initial Opioid Prescription Episode and the Likelihood of Long-Term Opioid Use among Opioid-Naïve Patients — United States, 2006–2015. MMWR. 66(10);265–269. PMID: 28301454
60. Heldenbrand SD, Dayer LE, **Martin BC**, O'Brien , Choi AN, Gubbins PO, Hawthorne J, Ramey M, Willis L, Flowers SK. (2018) Advanced Pharmacy Practice Experience Evaluation Scores are Positively Associated with Multiple-Mini Interview Score, Pre-pharmacy GPA and Pharmacy GPA. American Journal of Pharmaceutical Education, 82 (7): 818-825.
61. *Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, **Martin BC**. (2017) Comparative effectiveness of intra-articular hyaluronic acid and corticosteroid injections on the time to surgical knee procedures. J Arthroplasty. 32 (12), 3591-3597. PMID: 28781020
62. *Shewale AR, Barnes CL, Fischbach LA, Ounpraseuth ST, Painter JT, **Martin BC**. Comparative effectiveness of low, moderate and high molecular weight hyaluronic acid injections in delaying time to knee surgery. J Arthroplasty. 2017 Oct;32(10):2952-2957 PMID: 28606459
63. Dayer LE, Shilling R, Van Valkenburg M, **Martin BC**, Gubbins PO, Hadden K, Heldenbrand S. (2017) Assessing the Medication Adherence App Marketplace From the Health Professional and Consumer Vantage Points. JMIR mHealth and uHealth 5 (4), e45. PMID: 28428169

64. Hudson TJ, Painter JT, **Martin BC**, Austen MA, Williams JS, Fortney J, Sullivan MD, Edlund MJ. (2017) Pharmacoepidemiologic analyses of opioid use among OEF/OIF/OND veterans. Pain. 2017. PubMed PMID: 28195856.
65. Casciano B, Krishnan J, Small MB, Li C, Dotiwala Z, **Martin BC**. (2017) Progression to Uncontrolled Severe Asthma: A novel risk equation. J Manag Care Pharm. 2017; 23(1):44-50. PubMed PMID: 28025923.
66. Painter JT, **Martin BC**, Li C, Bodhani A, Pyne JM (2017) Genetic Testing for CYP-2D6 Polymorphism Prior to Selective Serotonin Reuptake Inhibitor Prescribing: Results from a Decision Analysis Model. J Psychiatry Cogn Behav: JPCB-123.
67. * Hammond DA, Kathe N, Shah A, **Martin BC**. Cost-Effectiveness of Histamine(2) Receptor Antagonists Versus Proton Pump Inhibitors for Stress Ulcer Prophylaxis in Critically Ill Patients. Pharmacotherapy. 2017 Jan;37(1):43-53. PubMed PMID: 27809338.
68. *Shah A, Shewale A, Hayes CJ, **Martin BC**. (2016) Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke; 2016; 47 (6): 1555-1561: PMID: 27103018.
69. Dayer L, Harrington S, **Martin BC**. Adherence to Adjuvant Neuropathic Pain Medications in a Palliative Care Clinic. J Palliat Med. 2016;19(5):538-41. PubMed PMID: 26835743.
70. Heldenbrand S, **Martin BC**, Gubbins PO, Hadden K, Renna C, Shilling R, Dayer L. (2016) Assessment of Medication Adherence Apps' Features, Functionality, Health Literacy Level and the Creation of a Searchable Web-based Adherence App Resource for Health Care Professionals and Patients. J Am Pharm Assoc. 2016;56(3):293-302. PMID: 27067551
71. Heldenbrand S, Flowers SK, Bordelon BJ, Gubbins PO, O'Brien C, Stowe CD, **Martin BC**. (2016) Multiple Mini-Interview Performance Predicts Academic Difficulty in the Pharm.D. Curriculum. Am J Pharm Education. 2016 Mar 25;80(2):27: PMID: 27073280
72. *Brown JD, Hutchison LC, Li C, Painter JT, **Martin BC**. (2016) Predictive Validity of the Beers and Screening Tool of Older Persons Potentially Inappropriate Prescriptions (STOPP) Criteria to Detect Adverse Drug Events, Hospitalizations, and Emergency Department Visits in the United States. J Am Geriatr Soc. 2016;64(1):22-30: PMID: 26782849
73. *Shewale AR, Johnson JT, Li C, Nelsen D, **Martin BC**. (2015) Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2015;24(12): 2845-53: PMID: 26482369
74. *Hayes CJ, Hudson TJ, Phillips MM, Bursac Z, Williams JS, Austin MA, Edlund MJ, **Martin BC**. (2015) The influence of propoxyphene withdrawal on opioid use in veterans. Pharmacoepidemiol Drug Saf. 2015 Nov;24(11):1180-8. PMID: 26248742.

75. *Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. (2015) Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation. Healthcare. 2015; 3(1):130-145.
76. *Ali MM, O'Brien CE, Cleves MA, **Martin BC**. (2015) Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study. Pharmacoepidemiology and Drug Safety. 2015; 24(4):435-45. PMID: 25683909.
77. *Patil PR, Wolfe J, Said Q, Thomas J, **Martin BC**. (2015) Opioid Use in the Management of Diabetic Peripheral Neuropathy (DPN) in a Large Commercially Insured Population. The Clinical Journal of Pain. 2015 May;31(5):414-24. PubMed PMID: 25853725
78. **Martin BC**, Shewale A. (2014) Validity of Electronic Prescription Claims Records: A Comparison of Commercial Insurance Claims with Pharmacy Provider Derived Records. Innovations in Pharmacy. 2014;5(4):1-13
79. Vanderlip E, Sullivan M, Edlund M, **Martin BC**, Fortney J, Austen M, Williams JS, Hudson T. (2014) National Study of Discontinuation of Long-Term Opioid Therapy among Veterans. Pain. 2014 Dec; 155(12): 2673-9. PMID: 25277462
80. Edlund MJ, Austen MA, Sullivan MD, **Martin BC**, Williams JS, Fortney JC, Hudson TJ. (2014) Patterns of opioid use for chronic non-cancer pain in the Veterans Health Administration from 2009 to 2011. Pain. 2014 Nov; 155(11): 2337-43. PMID: 25180008.
81. *Berger ML, **Martin BC**, Husereau D, Worley K, Allen JD, Yang W, Quon NC, Mullins CD, Kahler KH, Crown W. (2014) A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014 Mar;17(2):143-56. PubMed PMID: 24636373.
82. Dhamane AD, **Martin BC**, Brixner DI, Hudson TJ, Said Q. (2013) Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract. 2013 Sep;19(5):360-74. PubMed PMID: 24042242.
83. Casciano JP, Dotiwala ZJ, **Martin BC**, Kwong WJ. (2013) The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm. 2013 May;19(4):302-16. PubMed PMID: 23627576.
84. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, **Martin BC**. (2013) Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc. 2013 Mar-Apr;53(2):172-81. PubMed PMID: 23571625.
85. Dhamane AD, **Martin BC**, Brixner DI, Hudson TJ, Said Q. (2013) Metabolic monitoring of patients prescribed second generation antipsychotics. Journal of Psychiatric Practice. 2013. Sep;19(5):360-74. PubMed PMID: 24042242.

86. Li C, **Martin BC**, Cummins DF, Andrews LM, Frech-Tamas F, Yadao AM. (2013) Ambulatory resource utilization and cost for gout in the US. American Journal of Pharmacy Benefits. 2013;5(2):e46-e54.
87. Casciano JP, Singer DE, Kwong WJ, Fox ES, **Martin BC**. (2012) Anticoagulation therapy for patients with non-valvular atrial fibrillation: comparison of decision analytic model recommendations and real-world warfarin prescription use. Am J Cardiovasc Drugs. 2012 Oct 1;12(5):313-23. PubMed PMID: 22920047.
88. *Kelkar M, Cleves MA, Foster HR, Hogan WR, James LP, **Martin BC**. (2012) Prescription Acquired Acetaminophen Use and the Risk of Asthma in Adults: A Case Control Study. Annals of Pharmacotherapy. 2012 Dec;46(12):1598-608. PMID:23170033
89. Bhurke SM, **Martin BC**, Li C, Franks AM, Bursac Z, Said Q. (2012) Effect of the Clopidogrel-Proton Pump Inhibitor Drug Interaction on Adverse Cardiovascular Events in Patients with Acute Coronary Syndrome. Pharmacotherapy. 2012; 32(9):809-18. PubMed PMID: 22744772.
90. *Kelkar M, Cleves MA, Foster HR, Hogan WR, James LP, **Martin BC**. (2012) Acute and chronic acetaminophen use and renal disease: a case-control study using pharmacy and medical claims. J Manag Care Pharm. 2012 Apr;18(3):234-46. PMID:22468732
91. Said Q, **Martin BC**, Joish VN, Kreilick C, Mathai SC. (2012) The cost to managed care of managing pulmonary hypertension. J Med Econ. 2012;15(3):500-8. PMID:22313330
92. *Gokhale M, **Martin BC**. (2012) Prescription-acquired acetaminophen use and potential overuse patterns: 2001-2008. Pharmacoepidemiol Drug Saf. 2012 Feb; 21(2):226-30. (Epub ahead of print) PMID:21915939
93. Li C, **Martin BC**. (2011) Trends in emergency department visits attributable to acetaminophen overdoses in the United States: 1993-2007. Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):810-8. PMID: 21796717
94. **Martin BC**, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. (2011) Long-term chronic opioid therapy discontinuation rates from the TROUP Study. J Gen Intern Med. 2011 Dec;26(12):1450-7. PMID: 21751058
95. Richardson LP, Fan MY, McCarty CA, Katon W, Edlund M, DeVries A, **Martin BC**, Sullivan M. (2011) Trends in the prescription of opioids for adolescents with non-cancer pain. Gen Hosp Psychiatry. 2011 Sept-Oct;33(5):423-8. PMID: 21749839
96. Domino ME, **Martin BC**, Wiley-Exley E, Richards S, Henson A, Carey TS, Sleath B. (2011) Increasing time costs and copayments for prescription drugs: an analysis of policy changes in a complex environment. Health Serv Res. 2011;46:900-919. PMID:21306363
97. Sleath B, Domino ME, Wiley-Exley E, **Martin BC**, Richards S, Carey T. (2010) Antidepressant and antipsychotic use and adherence among Medicaid youths: differences by race. Community Ment Health J. 2010 Jun;46(3):265-72. PMID:20091226

98. Edlund MJ, **Martin BC**, Fan MY, Devries A, Braden JB, Sullivan MD. (2010) Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend. 2010 Nov 1;112(1-2):90-8. PMID: 20634006
99. Braden JB, Russo J, Fan MY, Edlund MJ, **Martin BC**, DeVries A, Sullivan MD. (2010) Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010 Sep 13;170(16):1425-32. PMID: 20837827
100. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, **Martin BC**. (2010) Risks for possible and probable opioid misuse among recipients of chronic opioid therapy in commercial and medicaid insurance plans: the TROUP Study. Pain. 2010 Aug;150(2):332-9. PMID: 20554392
101. Edlund MJ, **Martin BC**, Devries A, Fan MY, Braden JB, Devries A, Sullivan MD. (2010) An analysis of heavy utilizers of opioids for chronic non-cancer pain in the TROUP study. J Pain Symptom Manage. 2010 Aug;40(2):279-89. PMID: 20579834
102. Edlund MJ, **Martin BC**, Devries A, Fan MY, Braden JB, Sullivan MD. (2010) Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain. 2010 Jan;26(1):1-8. PMID: 20026946
103. Pathak P, Helm ME, **Martin BC**, Henderson C, West D. (2010) Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population: 2001-2005. Psychiatr Serv. 2010 Feb; 61(2):123-9. PMID: 20123816
104. Thielke SM, Simoni-Wastila L, Edlund MJ, DeVries A, **Martin BC**, Braden JB, Fan MY, Sullivan MD. (2010) Age and sex trends in long-term opioid use in two large American health systems between 2000 and 2005. Pain Med. 2010 Feb;11(2):248-56. PMID: 20002323
105. *Karve S, Cleves MA, Helm M, Hudson TJ, West DS, **Martin BC**. (2009) Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009 Sep;12(6):989-95. PMID: 19402852
106. Johnson ML, Crown W, **Martin BC**, Dormuth CR, Siebert U. (2009) Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report – Part III. Value Health. 2009 Nov-Dec;12(8):1062-73. PMID: 19793071
107. Karve S, Cleves MA, Helm M, Hudson TJ, West DS, **Martin BC**. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009 Sep;25(9):2303-10. PMID: 19635045
108. Cox E, **Martin BC**, Van Staa T, Garbe E, Siebert U, Johnson ML. (2009) Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: the International Society for Pharmacoeconomics and Outcomes Research Good Research Practices

for Retrospective Database Analysis Task Force Report--Part II. Value Health. 2009 Nov-Dec;12(8):1053-61. PMID: 19744292

109. **Martin BC**, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. (2009) Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009 Jan;43(1):36-44. PMID: 19126828
110. **Martin BC**, Church TS, Bonnell R, Ben-Joseph R, Borgstadt T. (2009) The impact of overweight and obesity on the direct medical costs of truck drivers. J Occup Environ Med. 2009 Feb;51(2):180-4. PMID: 19209039
111. *Karve S, Cleves MA, Helm M, Hudson TJ, West DS, **Martin BC**. (2008) An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008 Nov;46(11):1125-33. PMID: 18953222
112. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, **Martin BC**. (2008) Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008 Aug 31;138(2):440-9. PMID: 18547726
113. Braden JB, Fan MY, Edlund MJ, **Martin BC**, Devries A, Sullivan MD. (2008) Trends in use of opioids by noncancer pain type 2000-2005 among Arkansas Medicaid and HealthCore enrollees: results from the TROUP Study. J Pain. 2008 Nov;9(11):1026-35. PMID: 18676205
114. *Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, **Martin BC**. (2007) The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia. Curr Med Res Opin. 2007 Jun;23(6):1351-65. PMID: 17559734
115. Gold DT, **Martin BC**, Frytak JR, Amonkar MM, Cosman F. (2007) A claims database analysis of persistence with alendronate therapy and fracture risk in post-menopausal women with osteoporosis. Curr Med Res Opin. 2007 Mar;23(3):584-94. PMID: 17355739
116. **Martin BC**, Barghout V, Cerulli A. (2006) Direct medical costs of constipation in the United States. Manag Care Interface. 2006 Dec;19(12):43-9. PMID: 17274481
117. *Chen H, Reeves JH, Fincham JE, Kennedy WK, Dorfman JH, **Martin BC**. (2006) Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia Medicaid enrollees in 2001. J Clin Psychiatry. 2006 Jun;67(6):972-982. PMID: 16848658
118. *Provost M, Koopalum D, Dong D, **Martin BC** (2006). The initial development of the WebMedQual scale: domain assessment of the construct of quality of health web sites. Int J Med Inform. 2006 Jan;75(1):42-57. PMID: 16169770
119. *Sapra S, Nielsen K, **Martin BC**. (2005) The net cost of asthma to North Carolina Medicaid and the influence of comorbidities that drive asthma costs. J Asthma. 2005 July-Aug; 42(6):469-77. PMID: 16293542

120. *Chen H, Deshpande AD, Jiang R, **Martin BC**. (2005) An epidemiological investigation of off-label anticonvulsant drug use in the Georgia Medicaid Population. Pharmacoepidemiol Drug Saf. 2005 Sep;14(9):629-38. PMID: 15597329
121. Cook CL, Wade WE, **Martin BC**, Perri M 3rd. (2005). Concordance among three self-reported measures of medication adherence and pharmacy refill records. J Am Pharm Assoc. 2005 Mar-Apr;45(2):151-9. PMID: 15868757
122. Miller LS, **Martin BC**. (2004) Current and future forecasts of service use and expenditures of Medicaid-eligible schizophrenia patients in the state of Georgia. Schizophr Bull. 2004;30(4):983-95. PMID: 15954202
123. *Ganguly R, Kotzan JA, Miller LS, Kennedy K, **Martin BC**. (2004) Prevalence, trends and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004 Oct;65(10):1377-88. PMID: 15491242
124. **Martin BC**, Ganguly R, Panicker S, Frech F, Barghout V. (2003) Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin. 2003;19(8):771-80. PMID: 14687449
125. *Ganguly R, Miller LS, **Martin BC**. (2003) Future employability, a new approach to cost-effectiveness analysis of antipsychotic therapy. Schizophr Res. 2003 Sep 1;63(1-2):111-9. PMID: 12892865
126. Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, **Martin BC**, Stang P. (2003) A checklist for retrospective database studies -- report of the ispor task force on retrospective databases. Value Health. 2003 Mar-Apr;6(2):90-97. PMID: 12641858
127. *Nerurkar J, Wade WE, **Martin BC**. (2002) "Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty. Pharmacotherapy. 2002 Aug;22(8):990-1000. Review. PMID: 12173802
128. *Cantrell R, Young F, **Martin BC**. (2002) Antibiotic prescribing in ambulatory care settings for adults with colds, upper respiratory tract infections, and bronchitis. Clin Ther. 2002 Jan;24(1):170-82. PMID: 11833830
129. Kotzan JA, Maclean R, Wade W, **Martin BC**, Lami H, Tadlock G, Gottlieb M. (2002) Prevalence and patterns of concomitant use of selective serotonin reuptake inhibitors and other antidepressants in a high-cost polypharmacy cohort. Clin Ther. 2002 Feb;24(2):237-48. PMID: 11911554
130. **Martin BC**, Miller LS, Kotzan JA. (2001) Psychotropic prescription use and costs in the 1990s: current trends and five year time series forecasts. Schizophr Res. 47:281-292.
131. **Martin BC**, Chisholm MA, Kotzan JA. (2001) Isolating the cost of osteoporosis-related fracture for postmenopausal women. A population based study. Gerontology. 2001 Jan-Feb;47(1):21-9. PMID: 11244288

132. Boudinot SG, **Martin BC**. (2001) Online anatomy lab (oal): a self-regulated approach to the instruction of human anatomy. Interactive Multimedia Electronic Journal of Computer Enhanced Learning. 3(1): (<http://imej.wfu.edu/articles/2001/1/01/index.asp>)
133. **Martin BC**, Pathak DS, Sharfman MI, Adelman JU, Taylor F, Kwong WJ, Jhingran P. (2000). Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache. 2000 Mar;40(3):204-15. PMID: 10759923
134. Gedaly S, **Martin BC**, Arocho R, McMillan CA. (2000). The women pharmacists' health survey: preliminary results from a multi-regional survey of women pharmacists. Southern Journal of Health System Pharmacist. 4(3):5-12
135. **Martin BC**, Ricci JF, Kotzan JA, Lang K, Menzin J. (2000). The net cost of Alzheimer disease and related dementia: a population based study of Georgia Medicaid recipients. Alzheimer Dis Assoc Disord. 2002 July-Sep;14(3):151-9. PMID: 10994656
136. *Burgess S, **Martin BC**. (2000). Variations in childhood immunization rates for children aged 19-72 months. Southern Journal of Health System Pharmacists. 4(1):12-20.
137. Kotzan JA, **Martin BC**, Reeves JH, Wade W. (1999). The impact of race and fractures on mortality in a post menopausal Medicaid population. Clin Ther. 1999 Nov;21(11):1988-2000. PMID: 10890268
138. Battle YL, **Martin BC**, Dorfman JH, Miller LS (1999). Seasonality and infectious disease in schizophrenia: the birth hypothesis revisited. J Psychiatr Res. 1999 Nov-Dec;33(6):501-9. PMID: 10628526
139. Wade WE, **Martin BC**, Kotzan JA, Spruill WJ, Chisolm MA, Perri M. (2000). Formulary management of low-molecular-weight-heparins. Pharmacoeconomics. 2000 Jan;17(1):1-12. Review. PMID: 10747761
140. O'Connor CM, Radensky PW, Unger AN, **Martin BC**. (1999) Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. Clin Ther. 1999 Jul;21(7):1254-65. PMID: 10463522
141. *Ricci JF, **Martin BC**. (1999) Resource Utilization of Ischemic Stroke Patients: A Population Based Study of Georgia Medicaid Recipients. Journal of Research in Pharmaceutical Economics; 9(3): 21-34.
142. Kotzan JA, **Martin BC**, Wade WE. (1999) Persistence with estrogen therapy in a post menopausal Medicaid population. Pharmacotherapy. 1999 Mar;19(3):363-9. PMID: 10221376
143. **Martin BC**, Chisolm MA. (1999) Cross-validation of an instrument measuring pharmacy students attitudes towards pharmaceutical care. American Journal of Pharmaceutical Education. 63(1):46-51.
144. **Martin BC**, Miller LS. (1998) Expenditures for treating schizophrenia: a population-based study of Georgia Medicaid recipients. Schizophr Bull. 1998;24(3):479-88. PMID: 9718639

145. Kotzan JA, **Martin BC**, Poirier S, Nichols GJ, Perri M, Pritchard FL. (1997) Pharmaceutical care: community pharmacist attitudes and practices.” The American Journal of Integrated Healthcare, 1(1): 37-42.
146. Chisholm MA, **Martin BC**. (1997) Development of an instrument to measure students attitudes concerning pharmaceutical care. American Journal or Pharmaceutical Education. 61:374-379.
147. Kotzan JA, Perri MP, **Martin BC**. (1996) An assessment of Medicaid prior approval cost containment policies on prescription expenditures: a market share analysis of Medicaid and cash prescriptions. Journal of Managed Care Pharmacy. November/December;2(6):569-574.
148. Miller DW, **Martin BC**, Loo CM. (1996) Sumatriptan and lost productivity: a time series analysis of diary data. Clin Ther. 1996 Nov-Dec;18(6):1263-75. PMID: 9001842
149. *Misra S, Ricci JF, Gedaly SS, **Martin BC**, Horvath B. (1996) Evaluating health related quality of life in three disease management areas: asthma, diabetes, and hypertension. Journal of Managed Care Pharmacy. 2(4):408-13.
150. **Martin BC**, Perri M 3rd, Kotzan JA. (1996) Health care triage alternatives and the influence of health insurance, educations, and race. Patient Educ Couns. 1996 Aug;28(3):287-96. PMID: 8852104
151. **Martin BC**, McMillan JA, Kotzan JA. (1996) Bias associated with missing out-of-plan prescription data for Medicaid recipients: the whole truth. The Journal of Research in Pharmaceutical Economics. Quarter 3;7:65-77.
152. **Martin BC**, McMillan JA. (1996) The impact of a more restrictive prescription limit on Medicaid recipients: effects on cost, therapy, and out-of-pocket expenditures. Med Care. 1996 Jul;34(7):686-701. PMID: 8676607
153. Perri M, **Martin BC**, Pritchard FL (1995). Improving medication compliance: a practical intervention. The Journal of Pharmacy Technology. July/August; 11:167-72.
154. **Martin BC**, Dorfman JH, McMillan JA, McMillan CA. (1994) Prevalence of migraine headache and association with sex, age, race, and rural/urban residence: a population-based study of Georgia Medicaid recipients. Clin Ther. 1994 Sep-Oct;16(5):855-72. Discussion 854. PMID: 7859245
155. Jankel CA, McMillan JA, **Martin BC**. (1994) Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. Am J Hosp Pharm. 1994 Mar 1;51(5):661-6. PMID: 8203385
156. Jankel CA, **Martin BC**. (1992) Evaluation of six computerized drug interaction screening programs. Am J Hosp Pharm. 1992 Jun;49(6):1430-5. PMID: 1529984

157. Ortmeier BG, Wolfgang AP, and **Martin BC**. (1991) Career commitment, career plans, and perceived stress: a survey of pharmacy students. American Journal of Pharmaceutical Education. 55:138-42.

**PROFESSIONAL JOURNAL ARTICLES, EDITORIALS, COMMENTARIES,
LETTERS TO THE EDITOR** (¥ denotes invited articles)

158. Hayes CJ, Cucciare MA, **Martin BC**, Hudson TJ, Bush K, Lo-Ciganic W, Yu H, Charron E, Gordon AJ. Using data science to improve outcomes for persons with opioid use disorder. Subst Abus. 2022;43(1):956-963. doi: 10.1080/08897077.2022.2060446. PMID: 35420927.

159. Jain N, Phadnis MA, **Martin BC**, Mehta JL. Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. Am J Cardiol. 2021 Nov 2: S0002-9149(21) Epub ahead of print. PMID: 34740395.

160. Hayes CJ, Ortiz H, **Martin BC**, Hudson TJ, Robertson D, Aram J, Smith GR. Opioid Prescribing in Arkansas and Next Steps. J AR Medical Society. Mar 2018; 114(9): 200-202.

161. * Shewale AR, Fischbach LA, Hammond DA, **Martin BC**. Letter to the Editor on 'Hyaluronic Acid Injections in Medicare Knee Osteoarthritis Patients Are Associated With Longer Time to Knee Arthroplasty'. J Arthroplasty. 2017 Feb;32(2):696-697.

162. Brown JD, Hutchison LC, **Martin BC**. Commentary: Comparing the Tools to Identify Potentially Inappropriate Medications in the Elderly and Future Research Directions. Gerontology & Geriatrics Research. 2016; 5: 321.

163. **Martin BC**, Hayes C, Austen M, Hudson T. Author Response to “Impact of survival bias on opioid-related outcomes when using death as an exclusion criterion”. Pharmacoepidemiology and Drug Safety 2016; 25: 477–478.

164. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, **Martin BC**. Smartphone medication adherence apps: potential benefits to patients and providers: response to Aungst. J Am Pharm Assoc. 2013;53(4):345. PMID: 23892801

165. Pathak P, West D, **Martin BC**. (2010) Weighing the evidence for pediatric antipsychotic use. Psychiatr Serv. 2010 Mar;61(3):325. PMID: 20194416

166. **Martin BC**. (2005) ISPOR comments on the Medicare Rx Data Elements. ISPOR Connections, June;11(3):14.

167. Ganguly R, **Martin BC**, Dorfman J, Rizzo J. (2004) In search of an unbiased estimate of treatment effect using observational data: a comparison of propensity scoring and Heckman two stage sample selection models. ISPOR Connections: April;10(2):1-3.

168. ISPOR Retrospective Data Base Task Force (Chair: Motherall B; Members: Brooks J, Clark MA, Crown W, Davey P, Hutchins D, **Martin BC**, Stang P) (2001) ISPOR task force on

retrospective databases - checklist for retrospective database studies working paper. ISPOR News, August;7(4):4-7.

169. **Martin BC.** (2001) The women pharmacists' health study: preliminary results from a multi-regional survey of women pharmacists" Georgia Pharmacist Quarterly. Summer;78(3):2-11.
170. *Niecko T. **Martin BC.** (1999) The health insurance portability act of 1996: the issue of portable health care coverage. Journal of Managed Care Pharmacy. March/April;5(2):81-2.
171. * Cantrell R, **Martin BC.** (1998) The balanced budget agreement of 1997: children's health insurance program. Feature Article in The Georgia Pharmacy Journal, March;20(3):24-30.
172. ¥ **Martin BC**, Ricci JF, Misra S, Gedaly SS, Horvath B. (1996) Measuring quality of life: a primer for managed care pharmacists. Journal of Managed Care Pharmacy. July /August;4:415-22.
173. **Martin BC.** (1995) Evaluating health related quality of life. Georgia Pharmacist Quarterly,72(3):2,8.
174. **Martin BC** (1989) Acetaminophen in the news again: current concerns with renal effects. Illinois Pharmacist. 51(7):19-20.
175. **Martin BC.** (1989) Pharmacy Gone Temporary. Feature Article Illinois Pharmacist. 51(11):8-11.

PRESS RELEASES AND CONTRIBUTIONS TO PRESS

Contributed to 232 new stories from 190 outlets for the paper published in MMWR entitled, Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015, including Newsweek, CNN, Vox, Consumer Reports in 2017

Max Blau. STAT forecast: Opioids could kill nearly 500,000 Americans in the next decade. STAT. June 27, 2017. Contributed time series forecasts with Corey J Hayes.

PUBLISHED ABSTRACTS AND CONFERENCE PAPERS

1. Smith AM, Gomez-Acevedo H, Hayes CJ, Greer M, **Martin BC.** “Prediction with Rapid Evaluation and Development through Iterative Classifier Training/testing with Automated Reporting (PREDICT-AR): A modular platform for automated binary outcome prediction in big healthcare data.” A Poster Presented at the 2025 IQVIA Institute Research Forum. September 18th-19th, 2025.
2. Smith AM, Gomez-Acevedo H, Hayes CJ, Greer M, **Martin BC.** “Development of a Novel Approach to Improve Binary Classification Prediction Tasks When Encountering Time-To-

Event Data: Performance Comparison of Four Alternative Approaches To Predict Stimulant Use Disorder Among Persons Authorized To Purchase Medical Marijuana.” A Poster Presented at the 2025 IQVIA Institute Research Forum. September 18th-19th, 2025.\

3. Smith AM, Gomez-Acevedo H, Hayes CJ, Greer M, **Martin BC**. “Developing a Feature Selection Workflow for Variable-Rich Data: A Case Study Utilizing Claims Data to Build Classifiers for the Prediction of Opioid Use Disorder Among Persons Authorized to Purchase Medical Cannabis.” A Poster Presented at the 2025 IQVIA Institute Research Forum. September 18th-19th, 2025.
4. Thompson J, Farnam C, Daniels J, Noori K, Stanley N, Hudson T, Goudie A, **Martin BC**. Population Health Impact of the Introduction of Medical Cannabis in Arkansas. A Poster presented at the Academy Health Annual Research Meeting, Minneapolis, MN, June 9, 2025
5. Sundell J, **Martin BC**. Evaluating Rates of Hospital Acquired Infections through the COVID-19 Pandemic Using an Interrupted Time Series Model: Evidence from a Nationally Representative Claims Database. A poster presented at the Academy Health Annual Research Meeting. Minneapolis, MN, June 8, 2025
6. Wolde FT, **Martin BC**, Gressler LE, Li C, Acharya M, Hayes CJ. Impact of the X-Waiver Elimination on Buprenorphine Prescribing by Non-Physician Clinicians: An Interrupted Time Series Analysis. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 13th-16th, 2025. (Value in Health, 2025. 28 S207)
7. Rong R, Tang M, Lin Y, Gamble A, ElHassan NO, Xiong X, Shaffer JG, Acharya M, **Martin BC**, Hall JL, Fort D, Shi L. Identification and characterization of pregnancy episodes and outcomes using EHR data from an integrated healthcare delivery system in Louisiana. Poster presentation at the Society for Pediatric and Perinatal Epidemiology Annual Meeting, June 2025.
8. Smith AM, Gomez-Acevedo H, Hayes CJ, Greer M, **Martin BC**. “Development of a Discrete-Time-Updating Algorithm to Predict Cannabis Use Disorder Among Arkansas Medical Marijuana Cardholders.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 13th-16th, 2025. (Value in Health, 2025. 28 S287)
9. Smith AM, Gomez-Acevedo H, Hayes CJ, Greer M, **Martin BC**. “Development of a Novel Approach to Improve Binary Classification Prediction Tasks When Encountering Time-To-Event Data: Performance Comparison of Three Alternative Approaches To Predict Stimulant Use Disorder Among Persons Authorized To Purchase Medical Marijuana.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 13th-16th, 2025. (Value in Health, 2025. 28 S280)
10. Smith AM, Gomez-Acevedo H, Hayes CJ, Greer M, **Martin BC**. “Developing a Feature Selection Workflow for Variable-Rich Data: A Case Study Utilizing Claims Data to Build Classifiers for the Prediction of Opioid Use Disorder Among Persons Authorized to

Purchase Medical Cannabis.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 13th-16th, 2025. (Value in Health, 2025. 28 S274)

11. Porter A, Smith AM, Gokarakonda SB, Wilson MP, **Martin BC**. Empty Bottles, Rising Risks: A Case-Crossover Study On Psychotherapeutic Medication Depletion And Suicide Triggers. A poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) European Meeting. Barcelona, Spain, November 18, 2024.
12. Schootman M, Fuccello A, Corbin S, **Martin BC**, Mavros M. Venous thromboembolism diagnosis definition in claims data: implications for research. (Journal of Clinical and Translational Science, 2024, Vol 8(s1), 21)
13. KC G, **Martin BC**, Cucciare M. Lifetime Survival, Societal Costs and Cost-Effectiveness of Nine Options to Treat Alcohol Use Disorder ." Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, Atlanta, GA, May 6, 2024. (Value in Health, 2024, Vol. 27(6), p. S63-64)
14. F Wolde, C Hayes, L Gressler, **BC Martin**. The Impact of COVID-19 Preventive Restrictions on the Development of Diseases of Despair: A Multi-Group Time Series Analysis." Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, Copenhagen, Denmark, November 2023. (Value in Health, 2023, Vol. 26(12), p. S205.)
15. **Martin BC**, Hudson T, Goudie A, Farnan AC, Nooria K, Stanley N, Thompson JW. A Statewide Examination of Medical Marijuana Purchasing Patterns by Authorized Medical Condition. A Platform Presentation at the 2023 Addiction Health Services Research Conference, New York, NY. October 19, 2023.
16. Thompson JW. **Martin BC**, Hudson T, Goudie A, Farnan AC, Nooria K, Stanley N, Martin BC, Hudson T, Goudie A. Statewide Assessment of Medical Marijuana Uptake and Healthcare Integration. A Platform Presentation at the 2023 Addiction Health Services Research Conference, New York, NY. October 19, 2023
17. Hudson T, Goudie A, **Martin BC**, Farnan AC, Nooria K, Stanley N, Thompson JW. Who Qualifies for Medical Marijuana in Arkansas? Results From the First NIH-funded Population-level analysis of MMJ. A Platform Presentation at the 2023 Addiction Health Services Research Conference, New York, NY. October 19, 2023.
18. Goudie A, Thompson JW, **Martin BC**, Farnan AC, Nooria K, Stanley N, Hudson T. Impact of Medical Marijuana on Healthcare Utilization in PTSD Treatment. A Platform Presentation at the 2023 Addiction Health Services Research Conference, New York, NY. October 19, 2023.
19. Smith AM, **Martin BC**. “Exploring the Association between Diseases of Despair and Industry and Occupational Setting Among US Workers: A Cross-Sectional Study Using the Medical Expenditure Panel Survey, 2016-2020.” A Poster Presented at the International

Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA. May 17th, 2023. (Value in Health, 2023. 26 S204)

20. Smith AM, Peng C, Porter A, **Martin BC**. “The Role of Prescribed Controlled Substance Acquisition As Potential Triggers of Opioid Overdose: A Case-Crossover Study.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA. May 15th, 2023. (Value in Health, 2023. 26 S170)
21. Antonije Lazic, J Mick Tilford, **Bradley C Martin**, Mandana Rezaeiahari, Anthony Goudie, Ahmad Baghal, Melody Greer. In-Hospital Mortality by Race and Ethnicity Among Hospitalized Covid-19 Patients Using Data from the Us National Covid Cohort Collaborative. Seattle, WA. A Poster Presentation at the Academy Health National Conference. June 25, 2023. (Health Services Research 58 (4), 938-947)
22. Mavros MN, Johnson LA, Schootman M, Orcutt ST, Peng C, **Martin BC**. ASO Visual Abstract: Adherence to and Outcomes of Extended Venous Thromboembolism Prophylaxis After Complex Gastrointestinal Oncologic Surgery. (Ann Surg Oncol. 2023 Sep;30(9):5532-5533. PMID: 37428329.)
23. Jain N, **Martin BC**, Dai J, Phadnis MA, Al-Hindi L, Shireman TI. Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis a poster presented 2022 American Society of Nephrology Conference. (Kidney360 3 (8), 1374)
24. Smith A, **Martin BC**. “Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 17th, 2022. Washington DC. (Value in Health, 2022. 25 S394-S395)
25. C Peng, KK Zorn, M Acharya, M Bimali, **BC Martin**. Factors Associated with Cancer Prevention Surgeries for Hereditary Cancer Risk in Arkansas 2013-2018. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 17th, 2022. Washington DC. (Value in Health, 2022. 25 (7), S455)
26. **Martin BC**, Acharya M, Hayes C, Porter A, Turpin J, Bona JP, Utecht J, Hudson T. Predicting Fatal and Non-Fatal Opioid Overdoses with Prescription Drug Monitoring Program (PDMP). A poster presentation at the Addiction Health Services Research Virtual Conference. October 14, 2021.
27. Smith A, Acharya M, Hudson T, Hayes C, Porter A, Turpin J, Bona J, Utecht J, **Martin BC**. Evaluating the Temporal Association between the Recency of Prescribed Controlled Substance Acquisition and Fatal and Non-Fatal Opioid Overdose. A Poster Presented at the virtual International Society for Pharmacoeconomics and Outcomes Research International Meeting. June 1, 2021. (Value in Health, 2021; 24: S94)
28. publish “Statewide Trends in Genetic Testing for Hereditary Cancers in Arkansas 2013–2018”. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research Virtual Conference. May 18, 2021. (Value in Health, 2021; 24: S101)

29. Acharya M, **Martin BC**, Payakachat N. Utilization of Prescription Opioids and Benzodiazepines Among Arkansans With Medical Cannabis Identification Cards: A Matched Control Study. A Poster Presented at the virtual International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 1, 2020. (Value in Health, 2020. 23 S133-S134)
30. Acharya M, Chopra D, Marx CMA, Fritz JM, **Martin BC**, Early Care Decisions and The Risk Of Long-Term Opioid Use In Patients With Low Back Pain. A Poster Presented at the virtual International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 1, 2020. (Value in Health, 2020. 23 S214-215)
31. Chopra D, Williams JS, Austen MA, Bollinger M, **Martin BC** (2019). To Examine Association between Opioid Prescribing Patterns and Adjunct Services in Veterans' Administration Medical Centers in the U.S. A poster presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. New Orleans, LA, USA. May 21, 2019.
32. Hayes, CJ, Krebs EE, Hudson TJ, Brown J, Li C, **Martin BC** (2019). Impact of Opioid Dose Escalation on the Development of Substance Use Disorders and Other Adverse Outcomes: A Retrospective Cohort Study. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. New Orleans, LA, USA. May 21, 2019.
33. Acharya M, Chopra D, Hayes CJ, Teeter B, **Martin BC**. (2019) Cost Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. New Orleans, LA, USA. May 21, 2019.
34. Li X., Chaovalitwongse WA, Curran G, Tilford JM., Felix H, **Martin BC** (2018). Using Machine Learning to Predict Opioid Overdoses Among Prescription Opioid Users. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, MD, USA. May 21, 2018 (Value in Health, 21, S245).
35. Acharya M, and **Martin BC**. Degree of agreement between randomized controlled trials and observational studies on drug effects: a systematic review. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, MD, USA. May 21, 2018. (Value in Health, 21 (Suppl 1)).
36. Shah AB, Hayes CJ, Lakkad M, Martin BC. "Impact of Medical Marijuana Legalization on Opioid Use, Chronic Opioid Use and High-risk Opioid Use." A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, MD, USA. May 23, 2018. (Value in Health, 21 (Suppl 1)).
37. Chopra D, Bhandari NR, Kathe N, Moore G, Lewis K, Li C, Thompson JW, Goudie A, and **Martin BC**. Differences in Antidepressant Medication Management Between Commercially Insured And Traditional Medicaid For Low Income Adults In Arkansas. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes

Research International Meeting. Baltimore, MD, USA. May 22, 2018. (Value in Health, 21 (Suppl 1)).

38. Bhandari NR, Chopra D, Kathe N, Moore G, Lewis K, Li C, Goudie A, and **Martin BC**. Contrasting Utilization of Inpatient Hospitalizations and Emergency Department Visits Between Medicaid And Commercially Insured Arkansans. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, MD, USA. May 21, 2018. (Value in Health, 21 (Suppl 1)).
39. Kathe N, Chopra D, Bhandari NR, Moore G, Lewis K, Li C, Goudie A, and **Martin BC**. Examining the Impact Of Arkansas Medicaid Expansion Through Premium Purchase On Utilization Of Preventative Screening Services. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, MD, USA. May 21, 2018. (PHP67).
40. Kathe N, Bhandari NR, Chopra D, Moore G, Lewis K, Li C, Goudie A, and **Martin BC**. Impact of Arkansas Medicaid Expansion Through Premium Purchase On The Utilization And Access To Prenatal Visits. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Baltimore, MD, USA. May 21, 2018. (PIH42).
41. Chopra DA, Bhandari NR, Kathe N, Shah AB, Moore G, Li C, Thompson J, **Martin BC**. “Difference in Opioid Utilization between commercially insured and traditional Medicaid for low income adults.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, USA. May 23, 2017. (Value in Health, 20 (5), A229).
42. Shah AB, Goudie A, **Martin BC**. “The Influence Of Expanding Medicaid Through Commercially Obtained Insurance Versus Traditional Medicaid On Inpatient Utilization: A Comparison Of Arkansas And Kentucky.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 22, 2017. (Value in Health, 20 (5), A46).
43. Shah AB, Hayes CJ, **Martin BC**. “Which Pain Etiologies Are Most Likely To Result In Long Term Opioid Use? Results From A Large Nationally Representative Inception Cohort Study?” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 23, 2017. (Value in Health, 20 (5), A212).
44. Shewale AR, Barnes LC, Fischbach LA, Ounpraseuth S, Painter JT, **Martin BC**. “Conflicting Comparative Effectiveness Evidence Of Hyaluronic Acid Using Real World Data Evidence. An Update Using A High Dimensional Propensity Score Matching Approach.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 23, 2017. (Value in Health, 20 (5), A142).
45. Kathe NJ, Bhandari NR, Chopra DA, Moore G, Li C, Goudie A, **Martin BC**. “Contrasting Non-Emergent Care Delivered in Emergency Departments and Urgent Care Centers to

- Arkansas Medicaid and Private Option Enrollees”. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Boston, MA, USA. May 22, 2017. (*Value in Health*, 20 (5), A29).
46. **Martin BC**, Shah A. Initial Opioid Prescribing Characteristics and the Transitions from Acute to Long Term Opioid Use: Findings from Big Data. Podium Presentation at the Addiction Health Services Research, Seattle, Washington, October 14, 2016.
 47. Shah AB, Hayes C, **Martin BC**. Choice of First Opioid Prescription and the Transitions from Acute to Long Term Opioid Use—Findings from Big Data. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research European Meeting. Vienna, Austria, October 31, 2016. (*Value in Health* 19 (7), A598)
 48. Bhandari N, Kathe N, **Martin BC**. Cost of Healthcare Among Metastatic Lung Cancer Patients Receiving Chemotherapy NR Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research European Meeting. Vienna, Austria, October 31, 2016. (*Value in Health* 19 (7), A624-A625)
 49. Hayes CJ, Chopra D, Shah AB, **Martin BC**. Impact of State Mandated Queries of The Prescription Drug Monitoring Programs on Opioid And Non-Opioid Drug Related Adverse Effects: A Difference In Difference Approach (*Value in Health* 19 (7), A622)
 50. **Martin BC**, Shah AB, Kathe N, Moore G, Li C, Said Q, Goudie A, Thompson J. Determining The Feasibility of Using a Regression Discontinuity Approach to Compare Emergency Room Utilization Between Medicaid Fee-For-Service And Commercially Obtained Coverage In The ACA Medicaid Expansion Population. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 25, 2016. (*Value in Health*, 19 (3), A260).
 51. Shah AB, Kathe N, Moore G, Li C, Said Q, Goudie A, Thompson J, **Martin BC**. Determining The Feasibility Of Using A Regression Discontinuity Approach To Compare Inpatient Utilization Between Medicaid Fee For Service And Commercially Obtained Coverage In The Aca Medicaid Expansion Population. A Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 25, 2016. (*Value in Health*, 19 (3), A260).
 52. Shewale AR, Barnes LC, Fischbach LA, Ounpraseuth S, Painter JT, **Martin BC**. “Characterization of initial treatment strategies used to manage incident knee osteoarthritis.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. Washington, DC, USA. May 24, 2016. (*Value in Health*, 19 (3), A238).
 53. Kathe N, Hayes C, Shewale A, **Martin BC**. Cost Effectiveness Of Therapies For Castration Resistant Metastatic Prostate Cancer. Society of Medical Decision Making, St. Louis, MO, USA, Oct 18-21, 2015.
 54. Shilling R, VanValkenburg M, Renna C, Dayer L, **Martin BC**, Hadden K, Heldenbrand S. There are too many Apps for that: Development of a Website helps Patients and Providers

- find Quality Medication Adherence Applications. Forthcoming at the American Pharmacist Association Annual Meeting. Baltimore, MD, March 2016
55. Shah AB, Shewale AR, Hayes C, **Martin BC**. Cost effectiveness of dabigatran, apixaban, rivaroxaban, edoxaban and warfarin for ischemic stroke prophylaxis among patients with atrial fibrillation: us private payer's perspective (Poster PS2-7). Society of Medical Decision Making, St. Louis, MO, USA, Oct 18-21, 2015.
 56. Shewale AR, **Martin BC**. Comparative effectiveness of rivaroxaban and standard anticoagulant therapies for prevention of primary venous thromboembolism in patients with major orthopedic surgery. A Poster Presentation at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Philadelphia, PA, USA. May 16-20, 2015. (*Value in Health*, 18(3), A131)
 57. Hammond DA, Shah A, **Martin BC**. Cost-effectiveness of H2RAs versus PPIs for stress ulcer prophylaxis in critically ill patients. (Poster number: 370) Society of Critical Care Medicine Annual Congress. Orlando, FL, February 20, 2016. (*Crit Care Med*. 2015 Dec;43(12 Suppl 1):94.) and presented at Arkansas Association of Health System Pharmacists, October 8, 2015, Little Rock, AR.
 58. Shewale AR, **Martin BC**. Comparative effectiveness of rivaroxaban and standard anticoagulant therapies for prevention of primary venous thromboembolism in patients with major orthopedic surgery. A Poster Presentation at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Philadelphia, PA, USA. May 16-20, 2015.
 59. Dayer L, Harrington S, **Martin BC**. Adherence to adjuvant neuropathic pain medications in palliative care. American College of Clinical Pharmacy Virtual Poster Symposium. May, 2015. (*Pharmacotherapy* 2015; 35 (5): e 66-95.)
 60. Brown J, Painter J, Li C, Hutchison L, **Martin BC**. Predictive Validity of Inappropriate Prescribing Criteria for Adverse Drug Events, Hospitalizations, and Emergency Department Visits: A Time-To-Event Comparison of the Beers and Stopp Criteria. Poster presented at the 2014 International ISPOR Meeting in Amsterdam, Netherlands, November 10, 2014. (*Value in Health* 17 (7): A505).
 61. Brown J; Painter J; Li C; Hutchison L; **Martin BC**. Adverse Drug Events in the Elderly Occurring in Emergency, Inpatient, and Outpatient Departments in an Administrative Claims Database. Poster presented at the 2014 International ISPOR Meeting in Montreal, Canada, May 31-June 4, 2014. (*Value in Health* 17 (3): A155). Podium presentation at the 2014 Southern Pharmacy Administration Conference in Oklahoma City, OK, June 20-22, 2014.
 62. Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. Comparison of the guidelines and decision tool recommendations for oral anticoagulant use among patients with atrial fibrillation. A poster presented at the 19th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Montreal, QC, Canada. May 31-June 4, 2014. (*Value in Health*, Vol. 17 (3), A124)

63. Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. Comparison of atrial fibrillation decision support tools and guidelines used to guide anticoagulation therapy for patients with Nonvalvular Atrial Fibrillation. A poster presented at the 19th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Montreal, QC, Canada. May 31-June 4, 2014. Value in Health Vol. 17, Issue 3, Page A124

64. Shewale AR, Nelsen DA, Johnson JT, Li C, **Martin BC**. Net clinical benefit of the 2014 AHA/ACC/HRS Guideline used to guide anticoagulation therapy for patients with Nonvalvular Atrial Fibrillation. An abstract accepted for poster presentation at the Southern Pharmacy Administration Conference (SPAC) Oklahoma City, OK, June 20-22, 2014.

65. Potukuchi PK, Johnson JT, **Martin BC**, Hutchison LC, Bursac Z, Said Q. Impact of arthritis and other comorbidities on incidence of urinary incontinence: A case control study. Poster Presented at the 2014 ISPOR 19th Annual International Meeting in Montreal, Canada, June 4, 2014. Value in Health 17 (3): PUK6.

66. Potukuchi PK, **Martin BC**, Johnson JT, Hutchison LC, Bursac Z, Said Q. Treatment patterns of urinary incontinence in the presence of comorbidities. Poster Presented at the 2014 ISPOR 19th Annual International Meeting in Montreal, Canada, June 4, 2014. Value in Health 17 (3): PUK1.

67. Hayes C, Phillips M, **Martin BC**, Bursac Z, Hudson T. The Influence of the Propoxyphene Withdrawal on Opioid Use and Opioid Related Adverse Events in Veterans. Podium Presentation at the 2013 Addiction Health Services Research Conference, Portland, OR, October 25, 2013.

68. Ali M, O'Brien C, Cleves M, **Martin BC**. The Use of Montelukast and Neuropsychiatric Disturbances Among Pediatric Asthmatics: A Nested Case Control Study. Poster Presented at the 2012 European ISPOR Meeting in Berlin, Germany, November 7, 2012. Value in Health 15 (7): A559.

69. **Martin BC**, Fan MY, Edlund MJ, Richardson LP, Russo JE, DeVries A, Sullivan MD. Factors Associated With Chronic and Non-Chronic Opioid Initiation in Persons With Chronic Non-Cancer Pain" poster presented at the 31st Annual Scientific Meeting of the American Pain Society, May 17, 2012, Honolulu, HI

70. Patil P, Said Q, Thomas J, Wolfe J, **Martin B**. "A Descriptive Study of Opioid Use In The Management Of Diabetic Peripheral Neuropathy (DPN) In a Large Commercially Insured Population" poster presented at the ISPOR 17th Annual International Meeting in Washington, DC, June 2012, USA. Value in Health 15 (4) : A188.

71. Gokhale M, Cleves M, Foster H, James L, Hogan W, **Martin BC**. "Relationship Between Prescription Acquired Acute and Chronic Acetaminophen Use and Liver toxicity" poster presented at the ISPOR 14th Annual European Congress, November 2011, Madrid, Spain. Value in Health 14 (7):A391-A392.

72. Ali MM, **Martin BC**. “Trends In On-Label And Off-Label Prescribing Of Montelukast In A Commercially Insured Population 1998-2008” poster presented at the ISPOR 16th Annual International Meeting, May 2011 Baltimore, MD, USA. *Value in Health* 14(3):A15-A15
73. **Martin BC**, Casciano JP, Kwong WJ, Singer DE. Can a Model-Based Decision Support Tool Improve Anticoagulation Outcomes for Atrial Fibrillation? Results from a Large Database Cohort. Poster presented at the American Heart Association 2011 Scientific Sessions; November 13, Orlando, Florida. 2011.
74. Li C, **Martin BC**, Cummins DF, Andrews LM, Frech-Tamas F, Yadao AM. Ambulatory resource utilization and cost for gouty arthritis and gouty arthritis attacks. Poster presented at 2011 Annual Scientific Meeting of American College of Rheumatology/ Association of Rheumatology Health Professionals, Chicago, IL; November 4 -9, 2011.
75. **Martin BC**. Defining the clinical risks for bleeding in AF: Optimization of patient and treatment outcomes. Oral symposium presentation at the International Society on Thrombosis and Haemostasis. Kyoto, Japan, July 24, 2011.
76. Li C, **Martin BC**. Access to medical home and quality of care in adult diabetes patients. 8th World Congress of International Health Economics Association (iHEA), Toronto, Canada; July 10-13, 2011 (Oral presentation).
77. Li C, **Martin BC**. Disparity in access to usual source of care in adult diabetes patients. 2011 AcademyHealth Annual Research Meeting, Seattle, WA; June 12-14, 2011 (Poster presentation).
78. Bhurke S, **Martin BC**, Li C, Franks A, Bursac Z, Said Q. “The effect of interactions between clopidogrel and proton pump inhibitors on adverse cardiovascular outcomes in commercially insured patients with acute coronary syndrome” poster presented at ISPOR international meeting, Baltimore, MD, May 2011, *Value in Health*, 2011; 4: A34.
79. Said Q, **Martin BC**, Joish VN, Gabriel P, Kreilick C, Seal B, Williamson T, Mathai SC. Cost of Managing Chronic Thromboembolic Pulmonary Hypertension to Managed Care. Poster presentation at ISPOR 13th Annual European Congress, Prague, Czech Republic, November 6-9, 2010.
80. Said Q, **Martin BC**, Joish VN, Gabriel P, Kreilick C, Mathai SC. Cost of Managing Pulmonary Arterial Hypertension to Managed Care. Poster presentation at the 11th Annual Health Services & Outcomes Research Conference. Texas Medical Center, Houston, TX. December 9, 2010.
81. Bodhani A, Li C, **Martin BC**. Physician and patient factors predicting the prescribing of statins in hypertension and diabetes. *Value in Health*, May/June 2008; 11(3): A212.
82. Gokhale M, **Martin BC**. Temporal association between prescribed opioids and the national death rate due to opioid poisoning. A podium presentation at the Southern Pharmacy Administration Conference, Memphis, June 2010.

83. Gokhale M, **Martin BC**. Trends in prescription acquired acetaminophen use and overuse in a commercially insured population: 2001-2008. A poster presentation at the Southern Pharmacy Administration Conference, Memphis, June 2010.
84. Dhamane AD, **Martin BC**, Brixner DI, Hudson TJ, Said Q. Assessment of Metabolic Monitoring of Patients Prescribed Second Generation Antipsychotics Using Electronic Medical Record Data. Accepted for poster presentation at the ISPOR 15th Annual International Meeting, Atlanta, GA, May 15-19, 2010.
85. Rascati KL, **Martin BC**, Cheng L Severity Scoring: Comparison of Methods (workshop presentation). ISPOR 2nd Latin America Conference, Rio de Janeiro, Brazil, September 9-12, 2009.
86. Pyne JM, Bodhani A, **Martin BC**. “The Cost Effectiveness of Genetic Metabolic Screening Prior to Initiating Antidepressant Therapy.” Poster Presentation, February 2009, VA HSR&D Annual Meeting, Washington, DC.
87. **Martin BC**, Cox E. “The Validity of Electronic Prescription Claims Data: A comparison of electronic prescription claims records with pharmacy provider records” presented at the ISPOR 11th Annual European Congress, November 2008 Athens, Greece. *Value in Health*. 11(6):A564-A564.
88. Flannigan K, **Martin BC**. “A Natural Experiment To Estimate The Impact Of A Preferred Drug List Policy For Long Acting Narcotic Analgesics On Costs And Utilization” presented at the ISPOR 11th Annual European Congress, November 2008 Athens, Greece. (*Value in Health* 11.6 (2008): A648-A649)
89. **Martin BC**, Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath B. A New Measure of Adherence – the Daily Possession Ratio (DPR): Comparisons with the Medication Possession Ratio (MPR) in the presence of medication switching and therapeutic duplication. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Toronto, Canada, May 5, 2008. (*Value in Health* 2008; 11(3):A124-A125).
90. Parikh K, Li C, **Martin BC**. Factors Associated With Antihistamine Prescribing in Asthma in The United States during 2005. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Toronto, Canada, May 6, 2008. (*Value in Health* 2008; 11(3):A280).
91. Bodhani A, Li C, **Martin BC**. Physician and Patient Factors Predicting the Prescribing of Statins in Hypertension and Diabetes. Poster Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 13th annual meeting. Toronto, ON, Canada, May 6, 2008. (*Value in Health* 2008; 11(3): A212).
92. Pathak P, West DS, **Martin BC**, Helm M, Henderson C. An Investigation of Evidence-Based Use of Atypical Antipsychotics in Arkansas Medicaid. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research. Toronto, Canada. May 5, 2008. (*Value in Health* 2008; 11(3): A130-A131).

93. Conrad RC, Martin BC. Impact of 3-tier prescription copayment on prescription discontinuation and switching behavior of military beneficiaries. Joint Services Pharmacy Seminar. (*JAPhA* 2007; 47(5): 633).
94. Parikh K, Martin BC. Trends in Antihistamine Prescribing for Asthma in the United States from 1993-2004. Poster Presentation at the 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management annual meeting. Quebec City, Canada, August 20, 2007.
95. Martin BC, Pathak P, Helm M. The Impact of a Calcium Channel Blocker Preferred Drug List on Medicaid Prescription Expenditures and Utilization. Podium Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A3).
96. Martin BC, Karve SJ, Helm M. Having your Cake and Eating it Too: Results from a Policy Analysis of a Proton Pump Inhibitor Preferred Drug List. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A150).
97. Karve SJ, Martin BC. The Predictive Validity of Different Adherence Measures using Administrative Claims Data. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A85).
98. Bodhani A, Karve SJ, Martin BC. Trends in the Off-Label Prescribing of 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors in the United States: 1998-2004. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A48).
99. Pathak P, Martin BC. The Trends in Prescribing of Herbal Medicines in Ambulatory Settings in the United States 1993-2004. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Arlington, VA, May 21, 2007 (*Value in Health* 2007; 10(3):A25).
100. Martin BC, Karve S, Helm M. Costs Reductions Attained from an Evidence Based Preferred Drug List Policy on Less Sedating Antihistamines in a Medicaid Population. Poster presentation Academy of Managed Care Pharmacy Meeting, April 13, 2007. (*JMCP* 2007;13(2):175).
101. Martin BC, Pathak P, Helm M. Costs Reductions Attained from an Evidence Based Preferred Drug List Policy on HMG-CoA Reductase Inhibitors in a Medicaid Population. Poster presentation Academy of Managed Care Pharmacy Meeting, April 13, 2007. (*JMCP* 2007;13(2):175).

102. **Martin BC**, Hudson T, Constantine R, Wells J. Financial Evaluation of the Florida Medicaid Behavioral Pharmacy Management Program (BPMP). Poster presentation at the 2006 Medicaid Summit Conference, Park City, UT, September 28, 2006.
103. **Martin BC**, Karve S, Helm M. Costs Reductions Attained from an Evidence Based Preferred Drug List Policy on Less Sedating Antihistamines in a Medicaid Population. Poster presentation at the 2006 Medicaid Summit Conference, Park City, UT, September 28, 2006.
104. **Karve SJ, Martin BC**. Trends in Ambulatory Care Utilization for Constipation and Irritable Bowel Syndrome 1993-2003. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Philadelphia, PA, May 21, 2006. (*Value in Health* 2006; 9(3):A48).
105. **Chen H, Martin BC**. The Impact of Prescribing Off-Label Mood Stabilizers for Patients with Schizophrenia. Poster Presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Philadelphia, PA, May 21, 2006. (*Value in Health* 2006; 9(3):A72).
106. **Martin BC, Barghout V**. "Compliance and Persistence of Tamoxifen and Aromatase Inhibitors in Breast Cancer Patients." 5th European Breast Cancer Conference (EBCC), 21st - 25th March 2006, Nice, France.
107. **Chen H, Martin BC**. Prevalence and Factors Associated with the Off-Label Use of Antipsychotic, Antidepressant, and Anticonvulsant Medications among Georgia Medicaid Eligibles. Poster Presentation at the International Society for Pharmacoepidemiology (ISPE) annual meeting. Nashville TN, August 22, 2005. (*Pharmacoepidemiology and Drug Safety* 2005; 14(S2): S20-S21).
108. **Sapra S, Martin BC**. Impact of Anti-Allergic Medication on Asthma Costs in a Pediatric Population. Poster presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Washington DC, May 16, 2005. (*Value in Health* 2005; 8(3): 258).
109. **Cantrell RC, Martin BC**. Development and Validation of a Claims-Based Risk Assessment Model to Predict Pharmacy Expenditures in a Commercial Population. Poster presentation during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting. Washington DC, May 16, 2005. (*Value in Health* 2005; 8(3): 294).
110. **Martin BC, Barghout V**. The annual cost of constipation in the U.S. ambulatory and inpatient care settings. Poster presentation during Digestive Disease Week, McCormick Place in Chicago, Illinois, May 14-19, 2005.
111. **Martin BC, Barghout V**. National estimates of office and emergency room constipation-related visits in the United States. A Poster Presentation at the American College of Gastroenterology, Orlando, FL, October 2004.

112. **Martin BC, Barghout V.** National Estimates of Constipation Related Hospitalizations in the United States. A Poster Presentation at the American College of Gastroenterology, Orlando, FL, October 2004.
113. **Jiang J, Martin BC.** Cost-Effectiveness Analysis Comparing COX-2-specific inhibitors with conventional NSAIDs. Presented at the Southern Pharmacy Administration Conference 2004, Fort Lauderdale, FL, June 12, 2004.
114. **Martin BC, Miller LS, Dorfman J, Kotzan JA.** Advancing Risk Adjustment for Schizophrenia. Presented at the Annual International Society for Pharmacoeconomics and Outcomes Research European Conference, Barcelona, Spain. November 10, 2003.
115. **Ganguly R, Miller LS, Martin BC.** Prevalence and Trends in Antipsychotic Polypharmacy among Medicaid eligible Schizophrenia Patients in California and Georgia, 1998-2000. Presented at the 8th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington DC. May 19, 2003. (*Value in Health* 2003; 6(3): 347-8).
116. **Pannicker S, Nielsen K, Martin BC.** The Net Cost of Asthma to North Carolina (NC) Medicaid and Identification of Factors Driving Costs in an Asthmatic Population. Presented at the 8th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington DC. May 19, 2003. (*Value in Health* 2003; 6(3): 368).
117. **Ganguly R., Martin BC, Dorfman JH, Rizzo JA.** "In search of an unbiased estimate of treatment effect using observational data: A comparison of propensity scoring and heckman two stage sample selection models" A one hour workshop presented at the 8th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Washington DC. May 19, 2003.
118. **Koopalum D, Martin BC.** "Factors Influencing Inappropriate Antibiotic Prescribing for Children with Acute Bronchitis in Ambulatory Care Setting" a poster presentation at the 2002 International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress, Rotterdam, Netherlands, November 4, 2002 (*Value in Health* 2002; 5(6): 574-5) .
119. **Niecko T, Kotzan JA, DiPiro JT, Martin BC.** "Nonsteroidal Anti-Inflammatory Drug Exposure and the Relative Risk of Colorectal Cancer, Gastrointestinal and Renal Adverse Events" a podium presentation at the International Conference on Pharmacoepidemiology, Edinburgh, Scotland, August 21, 2002. (*Pharmacoepidemiology and Drug Safety* 2002; 11: s4).
120. **Provost M, Koopalum D, Dong D, Cox C, Martin BC.** "The initial development of the WebMedQual: a scale to assess the quality of health web sites" a poster presentation at the Drug Information 2002 Annual meeting, Chicago, IL.
121. **Panicker S, Barghout VE, Martin BC.** "The economic burden of Irritable Bowel Disease (IBS) to the North Carolina Medicaid program" a podium presentation at the Digestive Disease Weekly (DDW (2002)) Conference, San Francisco, California, May 22, 2002. (*Gastroenterology* 2002;122(4):A687).

122. Ganguly R, Martin BC. "Antipsychotic polypharmacy: Impact on cost and community tenure" a podium presentation at the Southern Pharmacy Administration 2002 Conference, Monroe, Louisiana, June 9, 2002.
123. Provost M, Koompalum D, Dong D, Cox C, **Martin BC.** "The initial development of the WebMedQual: a scale to assess the quality of health web sites" a poster presentation at the Southern Pharmacy Administration 2002 Conference, Monroe, Louisiana. Jun 8, 2002.
124. Pannicker S, Martin BC. "The net cost of asthma to the North Carolina (NC) Medicaid and the impact of varying case definitions" a poster presentation at the Southern Pharmacy Administration 2002 Conference, Monroe, Louisiana, Saturday, June 8, 2002.
125. Niecko T, Kotzan JA, DiPiro JT, Martin BC. "Nonsteroidal Anti-Inflammatory Drug Exposure and the Relative Risk of Colorectal Cancer, Gastrointestinal and Renal Adverse Events," a poster presentation at the Biomedical and Health Sciences Institute Annual Spring Symposium 2002: Cancer Research in Georgia, Athens, GA; June 3, 2002.
126. Pannicker S, Nielsen K, Martin BC. "The Net Cost of Asthma to a U.S. Public Medicaid Program," a podium presentation at the International Society of Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting, Cannes, France, November 13, 2001. (*Value in Health* 2001; 4(6): 419).
127. Ricci JF, Silverstein MS, Martin BC. "Development and validation of a prospective mortality risk adjustment casemix index using administrative drug information in ambulatory Medicaid populations," a podium presentation at the American Public Health Association, 129th Annual Meeting, Atlanta, GA, October 2001.
128. Ricci JF, Kotzan JA, Martin BC. "Development and validation of prospective mortality risk adjustment casemix indices using administrative drug information to supplement ICD-9-CM codes in ambulatory Medicaid populations," a poster presentation at the American Public Health Association, 129th Annual Meeting, Atlanta, GA, October 2001.
129. Fagan SC, Martin BC, Cantrell CR, Hess DC: "Secondary Stroke Prevention Gap." a poster presentation at the First National CDC Prevention Conference on Heart Disease and Stroke , Atlanta, GA, August 22-24, 2001. (*Preventive Med* 2001;33: S28).
130. Ganguly R, Barghout V, Frech F, **Martin BC.** "The Economic Burden of Irritable Bowel Syndrome to Medicaid" a poster presented at the 2001 American College of Gastroenterology annual meeting, Las Vegas, NV, October 23, 2001.
131. Ricci JF, Fagan S, Martin BC. "Development and Independent Validation of Prospective Mortality Risk-Adjustment Models for Incident Cases of Ischemic and Hemorrhagic Stroke Based on Automated Pharmacy and Medical Claims Data" a podium presentation at the American Neurologic Association Annual Meeting, Chicago, IL, Sept 30, 2001.
132. Martin BC, Silverstein MD, Ricci JF.. "Development and Independent Validation of Prospective Mortality Risk Adjustment Models for Alzheimer's and Related Dementias

Based on Automated Pharmacy and Medical Claims Data," a poster presentation at the American Neurologic Association Annual Meeting, Chicago, IL, Sept 30, 2001.

133. Ricci JF, Silverstein MS, Fagan SC, **Martin BC**. "Development and Validation of Prospective Cost Risk Adjustment Indices Using Administrative Medical and Drug Information for Stroke Patients in Medicaid Populations," a poster presentation at the Academy for Health Services Research and Health Policy, 2001 Annual Meeting, Atlanta, GA, June 2001.
134. Ricci JF, Silverstein MS, Kotzan JA, **Martin BC**. "Development and Validation of Prospective Cost Risk Adjustment Indices Using Administrative Medical and Drug Information for Medicaid Eligible Alzheimer's Dementia Patients," a poster presentation at the Academy for Health Services Research and Health Policy, 2001 Annual Meeting, Atlanta, GA, June 2001.
135. Ricci JF, Dorfman JH, **Martin BC**. "Development and Validation of Prospective Cost Risk Adjustment Indices Using Administrative Medical and Drug Information for Medicaid Populations," a poster presentation at the Academy for Health Services Research and Health Policy, 2001 Annual Meeting, Atlanta, GA, June 2001.
136. Ganguly R, Nerurkar J, **Martin BC**. "An assessment of the reliability and validity of the Cognitive Performance Scale (CPS) on the Medical Expenditure Panel Survey-Nursing Home Component" a poster presentation at the 2000 American Public Health Meeting, Boston, MA, November 15, 2000. (*pg 620 of the Meeting Program Announcement*).
137. Cantrell R, Young F, **Martin BC**. "Decision Analysis of Omeprazole versus Laparoscopic Nissen Fundoplication for Treating Patients with Severe Gastroesophageal Reflux Disease" a poster presented at the ISPOR Third Annual European Conference, Antwerp, Belgium, November 6, 2000. (*Value in Health. 2000; 3(5): 357*).
138. Nerurkar J, Wade WE, **Martin BC**. "Prophylaxis Against Deep-Vein Thrombosis and Fatal Pulmonary Embolism in Knee Arthroplasties: A Cost-Effectiveness Study" a poster presented at the ISPOR Third Annual European Conference, Antwerp, Belgium, November 5, 2000. (*Value in Health. 2000; 3(5): 313*).
139. Kotzan JA, **Martin BC**, Wade WE, Yu K. "GI Events Associate with NSAID Use in a Medicaid Population" a podium presentation at the 1999 American Association of Pharmaceutical Scientists Annual Meeting.
140. Cantrell R, Young F, **Martin BC**. "Antibiotic Prescribing in Ambulatory Care Settings for Adults with Colds, Upper Respiratory Tract Infections and Bronchitis" a podium presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
141. Gedaly S, Panicker S, Menon A, **Martin BC**. "Geographic Variations in the Rates of Total Joint Arthroplasty" a podium presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.

142. Ganguly R, Miller LS, **Martin BC**. “Cost-Effectiveness Analysis of Risperidone Using Work Status as an Outcome Measure” a podium presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
143. Cantrell R, Koompalum D, **Martin BC**. “Antibiotic Prescribing for Children with Colds, Upper Respiratory Tract Infections and Bronchitis in Ambulatory Care Settings” a poster presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
144. Joseph GJ, Banavali R, **Martin BC**. “Does the Lunar Cycle Affect the Need for Urgent Care? An Analysis of the 19996 NHAMCS Database” a poster presentation at the Southern Pharmacy Administration Conference, Austin, Texas, June 17, 2000.
145. Ricci JF, Dorfman JH, **Martin BC**. “Improving upon Modeling of Cost Outcomes” a podium presentation at the 1999 Society for Medical Decision Making Annual Meeting, Reno NV, October 4, 1999.
146. Glick HA, Polsky D, Schulman KQ, **Martin BC**, Oconner CM. “An Economic Evaluation of Amlodipine for the Treatment of Nonischemic Dilated Cardiomyopathy: The Prospective Randomized Amlodipine Survival Evaluation (PRAISE)” a podium presentation to the 4th European Meeting on Calcium Antagonists, Amsterdam, October 1999.
147. Radensky PW, O’Conner CM, Unger AN, **Martin BC**. “Hospital Utilization and Cost Among Patients with Nonischemic Heart Failure in the First Prospective Randomized Amlodipine Survival Evaluation Study (PRAISE)” a podium presentation to the 1999 International Society of Pharmacoeconomics and Outcomes Research annual meeting, May 1999 (*Value in Health*. 1999;2:129).
148. **Martin BC**, Pathak DS, Kwong WJ, Batenhorst AS, Sharfman MI. “Assessment of Responsiveness of the Migraine-Specific Quality of Life Questionnaire [Version 2.0]” a poster presentation at the Sixth Annual Symposium on Quality of Life Evaluation, Drug Information Association, Hilton Head, SC, March 1999.
149. Pathak D, **Martin BC**, Kwong J, Batenhorst A. Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ Version 2.0) using confirmatory factor analysis. (*Quality of Life Research*. 1998;7:647).
150. Battle YL, **Martin BC**, Dorfman JH, Miller LS. Seasonality and Infectious Disease in Schizophrenia: The Birth Hypothesis Revisited” a poster presentation at the 1999 International Congress on Schizophrenia Research, Santa Fe, NM, April 1999. (*Schizophrenia Research*. 1999;36:37).
151. **Martin BC**, Miller LS. “Six-Year Service Utilization and Expenditures of Medicaid Eligible Schizophrenia Patients In the State of Georgia” a poster presentation at the 1999 International Congress on Schizophrenia Research, Santa Fe, NM, April 1999. (*Schizophrenia Research*. 1999;36:346).

152. **Ricci JF, Martin BC.** "Development and Validation of Empirically Derived Risk-Adjustment Indexes for a Demented Population," a podium presentation at the 1998 Society for Medical Decision Making Annual Meeting, Boston, MA, October 1998. (*Medical Decision Making. 1998;18(4):476*).
153. **Martin BC,** Ricci JF, Kotzan JA, Menzin J, Lang K. "The burden of Alzheimer's Dementia to Georgia Medicaid" a podium presentation at the 1998 Neurology Outcomes Research: Current Science and Future Direction Conference, American Neurologic Association, Montreal, Canada, October, 1998. (*Annals of Neurology 1998;44(3):5*).
154. **Martin BC,** Sharfman M, Pathak D, Kwong J. "Assessment of Reliability of the MSQ, the Migraine Specific Quality of Life Questionnaire [Version 2.0]" a poster presentation at the 1998 Neurology Outcomes Research: Current Science and Future Direction Conference, American Neurologic Association, Montreal, Canada, October, 1998. (*Annals of Neurology 1998;44(3):p4*).
155. **Martin BC,** Chisolm MA. Validation of an Instrument to Measure Pharmacy Students Attitudes Concerning Pharmaceutical Care" an abstract accepted for a poster presentation at the 1998 American Association of College of Pharmacy Annual meeting, Snowmass, CO, July 21, 1998.
156. **Ricci JF, Martin BC.** "Development and Cross-Validation of a Comorbidity Index for a Stroke population" a podium presentation at the 1998 International Society for Pharmacoeconomics and Outcomes Research annual meeting, Philadelphia, PA, May 1998. (*Value in Health. 1998;1:33*).
157. **Martin BC,** Kotzan JA, Reeves J. "The Direct Medical Cost of Osteoporotic Fractures" a poster presentation at the 1998 International Society for Pharmacoeconomics and Outcomes Research annual meeting, Philadelphia, PA, May 1998. (*Value in Health. 1998;1:65*).
158. **Kotzan JA, Martin BC,** Reeves J. "Fracture Incidence in a Post Menopausal Female Medicaid Population" a podium presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
159. **Ricci JF, Martin BC** "Resource Utilization of Ischemic Stroke Patients: A Population Based Study of Georgia Medicaid Recipients" a podium presentation at the 1997 American Association of Pharmaceutical Scientist, Boston MA, November 1997.
160. **Kotzan JA, Martin BC,** Reeves J, Nichols G. "Hormone Therapy Compliance for Post Menopausal Medicaid Patients" a podium presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
161. **Oh S,** Ricci JF, Gedaly S, Cook C, Chaffee A, Misra S, Arocho R, McMillan CA, **Martin BC** "Preliminary Results from a Multi-Regional Survey of Women Pharmacists: Baseline estimates of Risk Factors and Disease Events" a poster presentation at the 1997 American Association of Pharmaceutical Scientist, Boston , MA, November 1997.

162. Burgess SM, Chaffee AD, **Martin BC** "Variations in Immunization Rates for Children" a poster presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, IN, November 1997.
163. Gedaly S, Oh S, Ricci JF, Cook C, Chaffee AD, Burgess S, Arocho R, McMillan CA, **Martin BC** "Results for a Multi-Regional Survey of Women Pharmacists. Focus on Spontaneous Abortion" a poster presentation at the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
164. Chaffee AD, Ricci JF, Gedaly S, Oh S, Cook C, Burgess S, Arocho R, McMillan CA, **Martin BC** "Prevalence and Risk Factors Associated with Migraine Headaches in Women Pharmacists: An Exploratory Analysis for a Multi-Regional Survey" an abstract printed in the 1997 American Association of Pharmaceutical Scientist, Boston, MA, November 1997.
165. Reeves JH, Kotzan JA, **Martin BC**, "The Impact of Fractures and Race On Mortality: A Retrospective Survival Analysis of Post-Menopausal Female Medicaid Recipients," an abstract accepted for a podium presentation at the 1997 American Public Health Meeting, Indianapolis, IN, November 9-13, 1997.
166. Boudinot SG, **Martin BC**, "Factors Influencing Pharmaceutical Calculations Grades: Is more study time better?" a poster presentation at the 1997 American Association of College of Pharmacy Annual meeting, Indianapolis, IN, July 15, 1997.
167. Ricci JF, Oh S, **Martin BC**, "Meta-Analysis, Markov Decision Tree, and Cost-Effectiveness Analysis on the Treatment of Essential Hypertension in the Elderly," and abstract accepted for a contributed podium presentation in the section entitled "Hypertension: Identification of Patients and Costs" of the Association for Pharmacoeconomics and Outcomes Research Annual Meeting, Philadelphia, PA, April 25, 1997.
168. **Martin BC**, Dorfman JH. "Bootstrapping Confidence Intervals and Mean Variances" a podium presentation at the 1996 Southeastern SAS users group, Atlanta, GA, October 14, 1996.
169. Ricci JF, **Martin BC**. "Institutionalized Resource Utilization of Ischemic Stroke Patients: A Population Study of Georgia Medicaid Recipients" a podium presentation at the 1996 Southern Pharmacy Administration Conference, Oxford, MS, May 31, 1996.
170. Misra S, Horvath B, Chaffee AD, **Martin BC**. "Variations in Immunization Rates for Children." a podium presentation at the 1996 Southern Pharmacy Administration Conference, Oxford, MS, May 31, 1996.
171. **Martin BC**. "Predicting Success in a Pharmacy Finance Course: Where Did you do your Pre-Pharmacy Curriculum?" a poster presentation at the 1996 American Association of College of Pharmacy Annual meeting, Reno, NV, July 17, 1996.
172. **Martin BC**. "Assessing Student Perceptions of Courses Offered by Pharmacy Care Administration" a poster presentation at the 1996 American Association of College of Pharmacy Annual meeting, Reno NV, July 17, 1996.

173. Misra S, Ricci JF, Martin BC, Gedaly S, Clark G, Kamath A, Horvath B. "An Appraisal of Generic Quality of Life Scales in Three Disease Management Areas: Hypertension, Diabetes, and Asthma," a poster presentation at the 1995 Academy of Managed Care Pharmacy, Washington, DC, November 1995.
174. Kotzan JA, Martin BC, Perri M. "A Market Share Analysis for Prior Authorized Medicaid Prescriptions," a podium presentation at the 1995 Annual American Association of Pharmaceutical Scientist.
175. Martin BC, Nadipelli V. "The Direct Medical Costs of Schizophrenia: A Population-Based Study of Georgia Medicaid Recipients," a poster presentation at the 1995 Association for Health Services Research Annual Meeting, Chicago, IL, June 1995.
176. Kotzan JA, Perri M, Martin BC. "Prescription Utilization for Medicaid Patients," a podium presentation at the 1995 American Pharmacy Association Annual Meeting, Orlando, FL, March 18, 1995.
177. Martin BC, Perri M, and Kotzan JA. "Care Seeking Behavior and the Role of the Pharmacist," a podium presentation at the 1995 American Pharmacy Association Annual Meeting, Orlando, FL, March 19, 1995.
178. Kamath AR, Martin BC, and Kotzan JA. "Documenting Pharmacist Interventions - A Telephonic Approach," a poster presentation at the 1994 Southern Pharmacy Administration Conference, Gainesville FL, June 4, 1994.
179. Martin BC and McMillan JA. "The Impact of A Finite Prescription Limit on Medicaid Recipients: Effects on Cost, Therapy, and Out-of-Pocket Expenditures," a poster presented at the 11th Annual Meeting of the Association for Health Services Research, San Diego, CA, June 13, 1994.
180. Martin BC and McMillan JA. "Bias Associated with Incomplete Data for Medicaid Recipients: The Whole Truth," poster presented at the 11th Annual Meeting of the Association for Health Services Research, San Diego, CA, June 13, 1994.
181. Martin BC and McMillan JA. "Revealed Preferences of Prescriptive Medicines," a poster presented at the 11th Annual Meeting of the Association for Health Services Research, San Diego, CA, June 13, 1994.
182. Perri M, and Martin BC "An Exploratory Study of a Practical Intervention for Improving Medication Compliance," Presented at the National Conference on Prescription Medicine Information and Education, Washington D.C., May 6, 1993.
183. Martin BC, McMillan JA, Dorfman JH, and Jankel CA "Prevalence of Migraine Headache in the Georgia Medicaid Population," A poster presentation at the American Public Health Association Annual Meeting, Washington, D.C., November 10, 1992.

184. McMillan JA, **Martin BC**, and Jankel CA, "Migraine-Related Utilization and Costs in A Medicaid Population," a poster presented at the Ninth Annual Meeting of the Association for Health Services Research, Chicago, Illinois, June 11, 1992.
185. Jankel CA, McMillan JA, and **Martin BC**, "The Cost of A Drug Interaction in Two Maryland Hospitals," a poster presented at the Ninth Annual Meeting of the Association for Health Services Research, Chicago, Illinois, June 11, 1992.
186. **Martin BC**, Jankel CA, and McMillan JA, "Selecting Ordinary Least Squares Estimators: A Case Examination of Collinear Control Variables," a podium presentation at the Southern Pharmacy Administration Conference, Auburn, Alabama, May, 1991.
187. **Martin BC** and Jankel CA, "Computer Drug Interaction Screening: An Evaluation of Current Software and Steps for Evaluating Software by Practitioners," a podium presentation at the 25th annual American Society of Hospital Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, December 4, 1990.
188. Ortmeier BG, **Martin BC**, and Wolfgang AP, "Stress Perception and Career Commitment: A Survey of Pharmacy Students," a poster presented at the 91st Annual Meeting of the American Association of Colleges of Pharmacy, Salt Lake City, Utah, July 10, 1990.

INVITED PRESENTATIONS AT INTERNATIONAL, NATIONAL, AND REGIONAL PRESENTATIONS

189. Hayes C, **Martin BC**. Association between opioid therapy trajectories and potential opioid-related adverse health events. Invited presentation to the National Academies of Sciences, Engineering, and Medicine (NASEM) open session of the second meeting on Evaluating the Effects of Opioids and Benzodiazepines on All-Cause Mortality in Veterans, taking place on March 9, 2022 Washington, DC.
190. Data Insights on Opioid Overdose Prevention and Harm Reduction: The Role of Prescribed Controlled Substances in Arkansas as Possible Triggers to Opioid Overdose. Plenary Speaker, 2022 Prescription Drug Abuse Prevention Summit, Hot Springs, AR. October 12, 2022.
191. Prescription Drug Misuse, Panelist, Southern Pharmacy Administration Conference, Houston TX, June 25, 2022.
192. Opioid use trajectories: An analysis of over 1 million non-cancer patients initiating opioids. Plenary Speaker. National Alliance of Medicare Set-Aside Professionals. MSP Policy Palooza, Baltimore, MD, September 27, 2017
193. The Opioid Epidemic. Plenary Speaker. Louisiana Department of Insurance Annual Health Care Conference. Baton Rouge, LA, September 7, 2017

194. Making Medical Decisions In An Irrational World. Plenary Address. 2016. International Society for Pharmacoeconomics and Outcomes Research International Conference, Washington, DC, May 24, 2016.
195. Opioids, A Friend for Life? Roundtable presented at the Southern Pharmacy Administration Conference. June 26, 2016.
196. Assessing the Evidence for the Health Care Decision Maker. Plenary Address. 2013 International Society for Pharmacoeconomics and Outcomes Research Conference, New Orleans, LA, May 20, 2013.
197. Assessing the Evidence Toolkit: Increasing the Reliability and Consistency of Evidence Evaluation. Webinar for Academy of Managed Care Pharmacy. October 30, 2013 & November 13, 2013.
198. Health evidence for decision making: assessment tool for prospective and retrospective observational studies. 2012 European ISPOR Conference, Berlin, Germany, November 5, 2012.
199. A proposed "measurement tool" for assessing retrospective observational studies for health care decision makers, Presented Moderator & Speaker: Bradley Martin, PhD, RPh, PharmD, Chair will be presented as one of the work products developed by Part 1 of the AMCP/ISPOR/NPC Comparative Effectiveness Research Collaborative Initiative, June 5, 2012, ISPOR International Conference, Washington DC
200. Eldessouki R, Berger M, Jansen J, Eddy D, Martin BC, Comparative Effectiveness Research Collaborative Initiative (CER-CI), Part 1- Interpreting Outcomes Research Studies for Health Care Decision Makers, Academy of Managed Care Pharmacy, April 20, 2012, San Francisco, CA
201. Michael Johnson Marc Berger, Muhammad Mamdani, Colin Dormuth, William Crown, PhD, Bradley Martin PhD, Emily Cox. Design and Analysis of Non-Randomized Studies of Treatment Effects using Secondary Databases. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Forum, Orlando, May 2009.
202. Direct Medical Costs of Constipation in the United States. GI Journal Club - National Internet CME presentation. March 5, 2007.
203. Martin BC, Barghout V. "Compliance and Persistence of Tamoxifen and Aromatase Inhibitors in Breast Cancer Patients." 2007 Presidents Day Weekend Breast Cancer Challenge. Branson, MO. February 19, 2007.
204. Martin BC. "Prescription Drug Event Data for Medicare Beneficiaries: A Glimpse of What the Part-D Research Data May Look Like" and invited podium presentation to the Student Forum of the International Society for Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 21, 2006.

205. Martin BC. "The Direct Costs of IBS and Constipation" Presented to the Novartis Health Outcomes Group, Newark, NJ, November 12, 2004.
206. Martin BC, Ganguly R, Dorfman J, Rizzo J. "In Search of an Unbiased Estimate of Treatment Effect Using Observational Data: A Comparison of Propensity Scoring and Heckman Two-Stage Sample Selection Models" an invited seminar presented to the Emory Cardiology Outcomes Group, Emory University, Atlanta GA, June 27, 2003.
207. Miller LS, Martin BC, Kotzan JA, Kennedy K, Ganguly R, Dorfman J. "Schizophrenia Treatment Patterns: Uses and limitations of Epidemiological Data sets," Invitational Address to the Psychology Department, University of South Alabama. April 11, 2003.
208. Martin BC. "The report of the ISPOR Retrospective Database Task Force" International Society for Pharmacoeconomics and Outcomes Research, Crystal City, VA, May 21, 2002.
209. Martin BC. "Economic and Clinical Management of H. Pylori Induced Peptic Ulcer Disease," Athens Area Health Plan Select HMO Physician Group, Athens, GA, November 11, 1998.
210. Martin BC. "How Much Does an Illness Cost? The Case of Osteoporosis and Alzheimer's Disease," an invited seminar presentation, Department of Clinical and Administrative, College of Pharmacy, Athens, GA, December 1998.
211. Martin BC. "Caveats with Administrative Data: Lessons learned from policy analyses and a study of schizophrenia" and invited seminar presentation, College of Pharmacy, The Ohio State University, February 23, 1998.
212. Kotzan JA, Martin BC, Reeves J, "Issues Relating to Osteoporosis in Post Menopausal Georgia Medicaid Patients" Georgia Department of Medical Assistance, July 23, 1997.
213. Martin BC, Radensky P, "Hospital Resource Utilization within a Clinical Trial for Congestive Heart Failure Patients" Outcomes Research Group, Pfizer Inc., New York NY, November 11, 1996.
214. Perri M, Martin BC, "Improving Medication Compliance: A Practical Intervention," Sterling Rice Consultants, Boulder CO, February 7, 1994.
215. Martin BC, "Pharmacokinetic Principles and Therapeutic Drug Monitoring," presented to Pharmacy Staff at Saint Anthony's Hospital, Rockford, Illinois, April, 1989.
216. Martin BC, "Treating Refractory Depression," presented to Psychiatric Medical, Pharmacy, and Nursing staff at the University of Illinois Hospital, Chicago, Illinois, December, 1988.

WEBINARS AND OTHER ONLINE PRESENTATIONS

217. Martin BC, Berger M. ISPOR Educational Webinar: A Tool for Assessing Evidence for Health Care Decisions I: Assessing Prospective and Retrospective Observational Studies, October 23, 2014
218. Martin BC. Assessing the Evidence Toolkit: Increasing the Reliability and Consistency of Evidence Evaluation. Webinar for Academy of Managed Care Pharmacy. October 30, 2013 and November 13, 2013.
219. Martin BC. Berger M. A Tool for Assessing Evidence for Health Care Decisions. Webinar for the International Society for Pharmacoeconomics and Outcomes Research . October 23, 2014.

GRANTS and RESEARCH CONTRACTS AWARDED

1. 5U54HD113159-02 NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (Shi - PI, Martin - Site PI) 10/01/24 – 09/30/26
RP3 Administrative Supplement - UAMS - evaluating the effectiveness and cost-effectiveness of Medicaid postpartum coverage extensions (MPE)

We will evaluate the effects of the Medicaid postpartum coverage extension in Louisiana and Mississippi, and postpartum depression screening mandate in Louisiana, compared to Arkansas. The intended outcome will be to evaluate the effectiveness and contextual factors of implementation strategies that aim to improve maternal postpartum health and health equity. This study will generate urgently needed data on practical, robust, and sustainable population-targeted strategies to improve maternal health outcomes, reduce maternal health risks, and eliminate maternal health disparities in the United States.

Total Cost: \$439,679

Role: **Site Principal Investigator**

2. PTC-2024-03 UAMS TRI CTSP2 Pilot (Elhassan/Martin - PI) 01/01/25 – 12/31/25
The Association of Medical Marijuana Use during Pregnancy with Adverse Neonatal Outcomes

Using statewide linked birth certificate, APCD and medical marijuana transaction data, this project will characterize medical marijuana purchasing characteristics and assess the influence of maternal medical marijuana purchases on peri-natal outcomes.

Total Cost: \$49,935

Role: **Co-Principal Investigator**

3. 5R01MH133857-02 NIH/NIMH (Thomsen – PI) 06/21/23 – 05/31/2026
The Impact of School Meal Delivery on Behavioral Disorders among Children in Health Disparity Populations

Using a novel longitudinal all-payer claims database linked to educational achievement and disciplinary outcomes, three aims are investigated: 1. Describe variation in medical diagnoses for ADHD, ODD, and CD across schools by race, ethnicity, gender, age, rurality, and neighborhood characteristics. 2. Quantify the effect of school meal delivery policies and medical diagnoses on disciplinary outcomes and academic achievement by race/ethnicity, rurality, and socioeconomic status. 3. Determine the effect of universal meals and breakfast after the bell, alone and in combination, on the likelihood of diagnosed childhood behavioral disorders and subsequent service utilization.

Total Cost: \$1,203,633

Role: **Co-Investigator**

4. 1R01DA054312-01 NIH/NIDA (Thompson/Hudson – PIs) 09/30/21 – 07/31/24
Population-Based Analyses of Healthcare Utilization and Outcomes in Users of Medical Marijuana

The goals of this project are to describe geographic, socioeconomic, and clinical characteristics of consumers of medical marijuana in Arkansas and to conduct a 12 month pre- and post- healthcare utilization and costs between consumers and non-cardholders.

Total Cost: \$1,296,965

Role: Co-Investigator

5. 273916 Arkansas Foundation for Medical Care (Martin – PI) 1/15/22 – 1/15/23

An exploration of Prescribed Controlled Substances as Opioid Overdose Triggers: An analysis of linked statewide Prescription Drug Monitoring Program (PDMP), Emergency Department, Inpatient and Death Certificated Data

Total Cost: \$54,947

Role: Principal Investigator

6. 1K2 HX003358 Veterans Administration (Corey Hayes PI) 10/01/2021-09/30/2026

Data to Clinical Action: Using Predictive Analytics to Improve Care of Veterans with Opioid Use Disorder Health Services Research and Development: Career Development Award-II (CDA-2)

Total Cost: \$1,002,627

Role: Mentor

7. UAMS Translational Research Institute (Zorn, Martin - CoPIs) 02/01/20-1/31/21

Assessing Statewide Variation in Hereditary Cancer Care Utilization in Arkansas

The study will use the Arkansas All-Payer Claims Database, which has de-identified patient care records from Medicaid, Medicare, private insurers and state employees. The data will help researchers better understand gaps in care.

Total Cost: \$49,992

Role: Co-Principal Investigator

8. 1502987-1 (SCMIRECC) Hudson (PI) 10/01/20 – 8/30/21

Linking Arkansas All Payers Claims Database (APCD) with Arkansas VA Data to Examine Impact of Opioid Health Policy on Rural Arkansans.

The goals of this project are to examine whether current opioid prescribing policies have had a differential impact on rural Veterans in Arkansas compared with their urban counterparts and examine the role of dual VA /non-VA healthcare coverage on Arkansans.

Role: Co-Investigator

9. UAMS Translational Research Institute, Hayes (PI) 01/1/19–3/31/20

Linking the Arkansas Prescription Drug Monitoring Program Data with the Arkansas All-Payer Claims Database

The overarching goal of this project is to develop data infrastructure to conduct future research on opioid use and abuse in Arkansas by integrating the Arkansas PDMP and APCD.

Role: Co-Investigator

10. TL1 TR003109 NCATS (James – PI)

7/1/19-6/30/24

Expanding Translational Research in Arkansas

Translational Research Institute helps researchers turn their ideas and findings into new medical treatments and other health interventions. Its focus is on rural Arkansas populations, where health and health care disparities persist. A major emphasis of the award is research partnerships with Arkansas communities to ensure that research supported by the institute aligns with the priorities and needs of Arkansans.

Total Cost: \$4,113,146

Role: Director of Data Scholars Program

11. 1R21CA231189-01A1 NIH/NCI (Teeter-PI)

04/01/19 – 03/31/21

Improving HPV Vaccination using Implementation Strategies in Community Pharmacies

The ultimate goal of this application is to develop care coordination between physicians and pharmacists to improve HPV vaccination rates among adolescents.

Total Cost: \$275,000

Role: Co-Investigator

12. NIDA 1 R36 DA046717-01 (Hayes - PI)

09/30/18-8/31/19

National Institute on Drug Abuse

Impact of Opioid Dosing Strategies on Pain Scores and Adverse or Unintended Clinical Outcomes

The central goal of this study is to determine the impact opioid treatment regimens have on patient reported pain scores and adverse or unintended clinical outcomes among patients with chronic, non-cancer pain (CNCP). This study will enhance our understanding of the long-term effectiveness of opioid prescribing patterns, namely dose escalations, reductions, and discontinuations. Using data from the Veterans Health Administration, this study proposal will first (Specific Aim 1) evaluate the effect of opioid dosage escalation on pain scores and adverse opioid outcomes (opioid and other drug-related accidents, overdoses, and injuries) associated with prescription opioid use. Secondly (Specific Aim 2), this study proposal will assess the difference in pain scores and unintended clinical outcomes among Veterans who discontinue chronic opioid use.

Total Cost: \$74,000

Role: Primary Mentor

13. UAMS College of Pharmacy Seed Grant (Payakachat - PI)

10/01/2018 – 09/31/2019

Opioid Use and Healthcare Resource Utilization among Older Adults with Arkansas Medical Cannabis Identification Cards

Total Cost: \$27,454

Role: Co-Investigator

14. BJA-2018-13607

11/21/18 - 9/30/20

Department of Justice/ (Hudson-PI)

Arkansas Department of Health

Prescription Drug Monitoring Program Enhancement

The central goal of this study is to enhance the Arkansas Prescription Drug Monitoring Program by creating an innovatively structured data repository to support current and future initiatives to improve safety of prescription drug prescribing in Arkansas. This study will include the creation of the data repository that links PDMP data, ED/hospitalization data, and death certificates (Aim 1); development of a risk prediction tool for identifying individuals at risk for opioid overdose using linked datasets (Aim 2); creation of a graphical user interface for the linked databases and risk prediction tool (Aim 3); and collaborate with PDMP Advisory Committee stakeholders to implement a state-wide campaign using the new tools created to increase awareness of opioid-overdose risk in Arkansas (Aim 4).

Total Cost: \$482,820

Role: Co-Investigator

15. PTC2017-06 (Teeter – PI)
NCATS

11/15/17 – 11/30/18

Testing Implementation Strategies to Support Community Pharmacist-Initiated Prescription and Distribution of Naloxone to Reduce Overdose of Opioids

The overarching goal of this study is to improve access to naloxone by using community pharmacies as prescribing and dispensing sites in order to prevent deaths caused by opioid overdose. The results of this study will be used to make additional changes to the materials and strategies and then create a “toolkit” that will be tested in a large implementation study in multiple pharmacies across Arkansas and the southern United States.

Total Cost: \$47,263

Role: Co-Investigator

16. UAMS Translational Research Institute Martin (PI) 04/01/18-4/30/18
Early Care Decisions and the Risk of Long-Term Opioid Use in Patients with Low Back Pain

Our interest is to identify potentially modifiable factors such as how opioids are prescribed and other management decisions including physical therapy made at the time of opioid initiation. Improved decision-making around these modifiable factors at the initiation of care may provide the best opportunity to prevent LTOU. In this pilot project we take an important step towards our goal by examining data from two state-wide all-payer claims databases (APCD), Arkansas and Utah, both with higher than average rates of opioid prescribing.

Total Cost: \$ 24,995

Role: Principal Investigator

17. UAMS Translational Research Institute Martin (PI) 06/01/17-4/30/18
A Predictive Tool of Adverse Events in Prescription Opioid Users

The overarching goal of this project is to develop tools that predict adverse outcomes among prescription opioid users and to build knowledge to implement these in clinical practice settings. We will utilize data from two administrative sources to identify predictors of opioid adverse events and utilize machine learning techniques to build opioid risk prediction tools. Total Cost: \$45,690

Role: Principal Investigator

18. 116MIR/NLR Veterans Administration South Central MIRECC Martin (PI) 07/1/15 – 12/31/16
Exploring Geographic Variation in High Risk Opioid Use and Opioid Prescribing Among Veterans

We will explore the geographic variability among VA Medical Center catchment area on opioid use and prescribing and identify VA system factors that influence opioid prescribing and use. Total cost, \$67,434

Role: Principal Investigator

19. UU Seed Grant: UU-UAMS-UK CTSA Brixner/Lasalle (PIs) 07/1/15 – 6/30/16
Feasibility of Establishing an Inter-Institutional Electronic Data Warehouse Cooperative: A Pilot Study to Assess the Quality of Care across Three CTSA Institutions

Our long-term goal is to leverage the EHR across multiple institutions, to measure, track and improve quality of care (e.g., antibiotic overuse). Our short-term objective is to develop an inter-institutional collaboration between the University of Utah, the University of Arkansas for Medical Sciences, and the University of Kentucky, three CTSA Enterprise Data Warehouse (EDW) hubs, to establish the feasibility of combining EHR data systems as a platform to compare quality metrics. It is our central hypothesis that a common data model can be implemented which will allow data sharing across institutions, ultimately leading to better tools to measure and improve quality. To explore the feasibility of combining data sources we will compare the quality of care across participating institutions based on a metric of antibiotic overuse for routine upper respiratory tract infections in ambulatory settings. Total Cost: \$27,000

Role: Co-Investigator

20. 1RO1DA034627-01A Edlund (PI) 5/15/2014 – 4/30/17
Prescribers, Pharmacists, & the Opioid Dilemma: a Multi-Site Qualitative Study

We will interview 60 primary care providers and 60 pharmacists in Arkansas, Idaho, Kentucky, and Washington about their decision-making processes regarding chronic opioid therapy for chronic non-cancer pain. The use of grounded-theory techniques will lead to developing models of primary care providers' and pharmacists' prescribing and dispensing behaviors and to develop specific recommendations for policy and interventions that our group and others can test in future studies to improve opioid-prescribing practice patterns, improve pain management, and decrease risk of opioid use disorders.

Direct cost first year: \$392,286, Total cost first year: \$455,397

Role: Co-Investigator

21. CMS-AR Medicaid Thompson (PI) 10/01/14 – 12/31/18
Arkansas Health Care Independence Program ("Private Option") Evaluation for Section 1115 Demonstration Waiver

The State of Arkansas implemented a novel approach to expand coverage for individuals newly eligible for Medicaid under the Patient Protection and Affordable Care Act (PPACA). Through a Section 1115 demonstration waiver, the State utilized premium assistance to secure private health coverage offered on the newly formed individual health insurance marketplace to those non-elderly adults who have incomes at or below 138 percent of the federal poverty level. This approach is commonly referred to as the “Private Option.” The objective of this evaluation will determine if the HCIP waiver improved access, improved care and outcomes, reduced churn, and was cost effective compared to traditional Medicaid expansion. Direct Cost Year 4 \$1,312,323, Total Cost: \$4,684,343

Role: **Director of Quality and Utilization Evaluation**

22. 1 UL1RR029884 James/Beck (PI) 07/1/2009 – 03/31/2015
Arkansas Center for Clinical and Translational Research Institute
University of Arkansas for Medical Sciences

Provides infrastructure support to enhance translational research including the conduct comparative effectiveness studies.

Direct costs first year: \$2,659,252, Total Costs first year: \$3,804,051

Role: **Director of Health Data Unit**

23. ACHI Martin (PI) 08/1/2014 – 7/31/2016
ACHI-UAMS Graduate Research Health Policy Analysis Fellowship, Arkansas Center for
Healthcare Improvement

The University of Arkansas for Medical Sciences College of Pharmacy, in collaboration with the Arkansas Center for Health Improvement seeks to establish the ACHI-UAMS Graduate Research Health Policy Analysis Fellowship. These two entities will be working collaboratively to support a post-graduate fellow to conduct and support health policy research in the state of Arkansas and nationally. The fellowship is renewable.

Direct Cost first year: \$37,500, Total Costs first year: \$37,500

Role: **Fellowship director**

24. 1 R01 DA030300-01 Edlund/Hudson (Dual PIs) 07/01/2010 to 06/30/2014
Use and Abuse of Prescription Opioids Among OEF/OIF Veterans

This project will utilize secondary data analysis of six years of VA administrative data (FY08-FY13), with separate analyses for OEF/OIF veterans and all veterans, to understand whether and how veteran-specific issues and system and provider factors affect likelihood of developing opioid use disorders (OUDs); and rigorously evaluate trends in chronic opioid use, misuse, and OUDs.

Direct costs first year: \$202,862, Total Costs first year: \$288,714, Total Costs 4 years: \$1,192,132

Role: **Co-Investigator**

25. Li C (PI), Martin BC (Co-I), Cummins D (Co-I) Ambulatory Resource Utilization for Gout and Gouty Arthritis Flares Protocol #: 131849, Novartis AG, 2/1/11 – 6/30/12, Total Cost: \$44,493, Role: **Co-Investigator**

26. Genetic Testing Decision Analysis Model for Antidepressant Treatment”. VA HSR&D Short-Term Project. Jeff Pyne, MD, PI. Brad Martin, PharmD, PhD, Co-I. Direct costs: \$29,084. April – September, 2008. Role: **Co-Investigator**
27. Helm M (PI), West DS (Co-I), Martin B (Co-I), Vanderbush R (Co-I). “Title: Improving Medication Prescribing for Arkansas Children through Off-label Education Start Date: May 1, 2007 through April 30, 2009. General Consumer and Prescriber Education Grant Program, Center for Evidence-based Policy, Oregon Health Sciences University, \$373,362, **Co-Investigator**.
28. Martin BC (Co-PI), Mays G (Co-PI), Hudson T (Co-I), Booth B (Co-I), Golden W (Co-I), Thompson J (Co-I), Steffick D (Co-I), Owen R (Co-I). UAMS Consortium for Health Service Research. Agency for Health Care Research and Quality. 5P20HS015878-02 Awarded June 1, 2006. First year funding \$249,423, total funding requested over 2 years. \$495,658. **Principal Investigator**.
29. Sullivan M (PI), Edlund M (Co-I), Martin BC (Co-I), DeVries A (Co-I), Fan MY (Co-I). Risks for Opioid Use and Abuse in Contrasting Chronic Pain Populations. National Institute on Drug Abuse. 09-30-06 to 09-30-10. 1 R01 DA022560-01. First year funding: \$295,272, **Co-Investigator**. \$1,023,373.
30. Domino M (PI), Carey T, Sleath B, Martin BC. Duration of Prescribed Medication and Adherence to Medications for Chronic Diseases, 2 year research grant. Submitted to the Robert Wood Johnson Changes in Healthcare Financing and Organization Initiative. \$174,527, UAMS Subcontract to University of North Carolina, **Co-Investigator**. \$40,891.
31. Hong SH (PI) Franks AM, (Co-I) Martin BC (Co-I). An Examination of Guideline Concordant and Discordant Calcium Channel Blocker Prescribing among Hypertensive Patients with High Risk Conditions. Novartis Pharmaceuticals Corporation. July 2005 – June 2006. **Co-Investigator** \$78,136.
32. Martin BC (PI). Utilization Patterns and Persistence of Antihormonal Therapies for Breast Cancer. Submitted to Novartis Pharmaceuticals Corporation, Awarded November 2005. 2005. **Principal Investigator**. \$24,492.
33. Hong SH (PI), Martin BC. Time and Healthcare Costs Needed to Reach Blood Pressure Control. Holston Medical Group. 2005. Awarded June 2005. **Co-Investigator**. \$40,303
34. Hudson T (PI), Martin BC (Co-PI), Owen R (Co-I), Steffick D (Co-I), Phillips M (Co-I). Evaluation of the Florida Medicaid Behavioral Pharmacy Management Program. Submitted to University of South Florida, Florida Mental Health Institute (FMHI). Notification of award March 8, 2005 – Research to Initiate November 2005. **Co-Principal Investigator** \$272,177.
35. Martin BC (PI). An Evaluation of the Effect of a Prior Authorization Requirement for Atypical Antipsychotic Medications in the Georgia Medicaid Program. Boston Health Economics. 2004-2005. Awarded November 2004. **Principal Investigator** \$18,260.

36. Martin BC (PI). An Evaluation of the Effect of a Prior Authorization Requirement for Atypical Antipsychotic Medications in the Georgia Medicaid Program. Boston Health Economics. 2003-2004. Awarded January 2004. **Principal Investigator** \$55,239.
37. Ganguly R and Martin BC. Antipsychotic polypharmacy: Impact on cost and community tenure; 2003; (**Major Professor and Faculty Supervisor**) Agency for Health Care Research and Quality - Dissertation Grant, Submitted August 15, 2002; Project was approved and funded but could not be accepted since R Ganguly graduated at the time of the award notification, May 2003.
38. Kotzan JA, Fick D, Martin BC, Franic D, Wade W, "Pharmaceutical Outcomes Research Program", University of Georgia, Medical College of Georgia Joint Intramural Grants Program, **Co-Investigator**, \$16,416
39. Martin BC, Miller LS, Kotzan JA, Dorfman JH. Advancing Risk Adjustment for Schizophrenia; Agency for Healthcare Research and Quality, RO3 HS10815-01, 07/00 - 01/02, **Principal Investigator**, \$72,400.
40. Kotzan JA, Franic D, Martin BC, Wade WE. Prevalence of Cancer within the Georgia Medicaid Population; AstraZeneca, **Co-Investigator**, \$30,000.
41. Kotzan JA, Maclean JR, Martin BC, Wade WE. Pharmaceutical Outcomes Research Program; Joint Intramural Grants Program, University of Georgia Research Foundation and the Medical College of Georgia, 10/01-6/03, **Co-Investigator**, \$73,144.
42. Martin BC and Kotzan JA. Cost of Asthma and Comparative Outcomes in the Georgia Medicaid Population, Unrestricted Educational Grant; Glaxo Wellcome, 09/00 - 06/01, **Principal Investigator**, \$5,000.
43. Kotzan JA, Maclean R, Wade W, Martin BC, Imai H, Tadlock G. Drug Utilization: A review of patterns of prescribed medication among highest prescription users; 1999-2000 (funded 11/99), **Co-Investigator**, \$19,865.
44. Martin BC and Kotzan JA. The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 1999-2002, Athens Area Health Plan Select; (funded 10/99), **Primary Fellow Supervisor (PI)**, \$18,000/year: total funding 72,000.
45. Kotzan JA, Wade W, Martin BC. "Determination of Gastrointestinal Bleeding Associate with Chronic Use of Nonsteroidal Anti-Inflammatory Agents in the Georgia Medicaid Population" Merck and Company; 1998-99, **Co-Investigator** (funded 11/98), \$14,044.
46. Martin BC and Kotzan JA. The Managed Care Pharmacy Fellowship: Sponsored by Athens Area Health Plan Select; 1998-99, Athens Area Health Plan Select; (funded 10/98), **Primary Fellow Supervisor (PI)**, \$18,000.
47. Martin BC, Kotzan JA, Ricci JF. Alzheimers Dementia: A Cost of Illness Study; 1997-98; **Principal Investigator (PI)**, Boston Health Economics; (funded 6/97), \$32,500.

48. Chisholm MA, Dipiro JT, May R, Martin BC, Optimizing Renal Transplant Medication Outcomes and Compliance Through Pharmacists Intervention, 1997-1999, **Co-Investigator**. The Mason Trust, (funded 12/96), \$331,853.
49. Martin BC and Miller LS. Schizophrenia in the Medicaid Population: A Cost of Illness Study, 1996-1998, **Principal Investigator**, American Association of Colleges of Pharmacy New Investigator Awards, (funded 8/96), \$9,964.
50. Martin BC, Chisolm M, Wade W. A Pharmacists Mediated Peptic Ulcer Disease (PUD) Management Program Within a Corporate Patient Population: An Integrated Approach, 1996-1999, **Principal Investigator**, Wal-Mart, \$35,615.
51. Kotzan JA and Martin BC. The Economic Burden of Osteoporosis and Pharmacoeconomic Impact of Alendronate: A Population Based Study of Georgia Medicaid Recipients, 1996-1997, **Co-Principal Investigator**, Merck and Co., \$19,857.
52. Kotzan JA and Martin BC. Medicaid Database - Analysis for Depression; 1996, **Co-Principal Investigator**, The Medstat Group, \$25,393.
53. Martin BC. A Market Share Analysis of Pharmaceutical Use for Georgia Medicaid Patients Suffering from Dementia; 1995-1996, **Principal Investigator**, Janssen Pharmaceutical Research Foundation, \$8,100.
54. Kotzan JA, Perri M, Martin BC, Poirier S, Pritchard FL. Attitudes and Current Pharmaceutical Care Practices of Community Pharmacists; 1995, **Co-Investigator**, University of Georgia College of Pharmacy, \$7,500.
55. Martin BC. The Economic Burden of Schizophrenia: A Population Based Study of Georgia Medicaid Recipients; 1994-95, **Principal Investigator**, Janssen Pharmaceutical Research Foundation, \$10,714.
56. Martin BC and Kotzan JA. A State-Wide Network for Recording Pharmacist Interventions; 1993-94, **Co-Principal Investigator**, The Georgia Pharmacy Foundation, \$5,181.
57. Perri M, Martin BC, Pritchard FL. Improvements in Medication Compliance: A Practical Intervention; 1993-94, **Co-Investigator**, The West Company, \$26,600.
58. Martin BC under the supervision of McMillan JA. The Impact of a Finite Prescription Limit on Georgia Medicaid Recipients: An Economic Analysis; 1992-93 **Principal Investigator**, Glaxo, Inc. \$1,635.
59. Martin BC under the supervision of McMillan JA. The Impact of a Finite Prescription Limit on Georgia Medicaid Recipients: An Economic Analysis; 1992-93 **Principal Investigator**, The UpJohn Co. \$1,135.
60. McMillan JA and Jankel CA. Burden of Migraine on the Georgia Medicaid Population; 1991-92; (**Research Associate**) Glaxo, Inc. \$21,332.

61. Jankel CA and McMillan JA. Cost of Drug Interactions in Two Maryland Hospitals; 1990-91; (**Research Associate**) Glaxo, Inc. \$14,341.
62. Jankel CA. An Evaluation of Drug Interaction Screening (CDIS) Programs; 1990-91; (**Research Associate**) University of Georgia Faculty Research Grant; \$6,000.

RECOGNITIONS, AWARDS, OUTSTANDING ACHIEVEMENTS, and LICENSURES

Graduate Faculty of the Year, UAMS Graduate School, 2022.

Poster selected for Spotlight presentation and finalist for poster award. Smith A, **Martin BC**. “Cost-Effectiveness Analysis of Ruxolitinib vs Best Available Therapy for the Treatment of Myelofibrosis in the United States.” A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. May 17th, 2022. (Value in Health, 2022. 25 S394-S395)

ERCSP's inaugural 2021 Best Paper Award:

Teeter BS, Mosley C, Thomas JL, **Martin B**, Jones D, Romero JR, Curran GM. (2020) Improving HPV vaccination using implementation strategies in community pharmacies: Pilot study protocol. Res Social Adm Pharm. 2020 Mar;16(3):336-341.

Finalist (Top 3) for the 2020 Tufts-Center for the Evaluation of Value and Risk in Health Cost-Effectiveness Analysis Paper of the Year Award. Acharya M, Chopra D, Hayes CJ, Teeter B, **Martin BC**. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 Apr;23(4):451-460. PMID: 32327162.

Arkansas HealthCare Heroes, Health Professional Hero of the Year, 2019

Nominated for poster finalist award: Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. A Poster Presented at the International Society for Pharmacoeconomics and Outcomes Research International Meeting. New Orleans, LA, USA. May 21, 2018

1st place poster presented at PMRG (Pharmaceutical Marketing Research Group), 2017 Institute conference, October 2-4, 2017: Shah A, Shewale A, Hayes CJ, Martin BC “Cost Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis among Nonvalvular Atrial Fibrillation Patients”

Investigator Award, Substantial Contributions to the Literature of Clinical Pharmacy. Arkansas College of Clinical Pharmacy, 2016.

ISPOR Distinguished Service Award: Program Committee Co-Chair, 2016

Best Poster Presentation: Hammond D, Kathe N, Shah A, Martin BC. Cost Effectiveness of H2RAs versus PPIs for Stress Ulcer Prophylaxis in Critically Ill Patients. Southern Pharmacy Administration Conference, Oxford MS, June 26, 2016.

Best Student Poster Presentation Award: Shewale AR, Martin BC. Comparative effectiveness of rivaroxaban and standard anticoagulant therapies for prevention of primary venous thromboembolism in patients with major orthopedic surgery. A Poster Presentation at the 20th Annual International Society for Pharmacoeconomics and Outcomes Research Conference, Philadelphia, PA, USA. May 16-20, 2015.

Finalist for Society of Medical Decision Making Lusted Student Award: Shah AB, Shewale AR, Hayes C, Martin BC. Cost effectiveness of dabigatran, apixaban, rivaroxaban, edoxaban and warfarin for ischemic stroke prophylaxis among patients with atrial fibrillation: us private payer's perspective (Poster PS2-7). Society of Medical Decision Making, St. Louis, MO, USA, Oct 18-21, 2015.

ISPOR Distinguished Service Award: Task Force Chair Assessing Retrospective Studies for Health Care Decision Makers 2014

ISPOR Distinguished Service Award: Short Course Development and Quality Assurance Committee Chair (2012-2014)

Exceptional Reviewer: JMCP – 2013, 2017

Exceptional Reviewer: J Pharmacoepi and Drug Safety - 2012

Best Student Poster Award: A Natural Experiment to Estimate the Impact of a Preferred Drug List Policy for Long Acting Narcotic Analgesics on Costs and Utilization. Flannagin KR, Martin BC. 2008 International Society for Pharmacoeconomics and Outcomes Research European Conference, Athens, Greece.

AACP-AFPE Pharmacy Faculty New Investigator, 2004

American Society of Health System Pharmacy Foundation 2003 Pharmacy Practice Research Award for the research manuscript: Nerurkar J, Wade WE, **Martin BC.** (2002) "Costs Per Death Averted with Venous Thromboembolism Prophylaxis in Patients Undergoing Knee Arthroplasty or Replacement." Pharmacotherapy. 22(8): 990-1000.

AFPE Fellow: Awarded by the American Foundation for Pharmaceutical Education in 2004. Recognized as one of the Top 5% Reviewers for Journal of Managed Care Pharmacy, 2003.

Faculty Advisor for the UGA AMCP student chapter P&T competition team of Hua Chen, Jorie Cristy, Patrick Ellis, Taylor Rice who took First place at the National AMCP Competition held in Minneapolis MN on April 11, 2003.

Nominated for Best Poster Presentation at the 2003 International Society for Pharmacoeconomics and Outcomes Research Conference for the following presentation: Pannicker S, Nielsen K, **Martin BC.** "The Net Cost Of Asthma To North Carolina (NC)

Medicaid And Identification Of Factors Driving Costs in An Asthmatic Population.”
Washington DC. May 19, 2003.

Career Development Certificate of Recognition for greatly contributing to the career development of UGA students, September 1, 2003.

Nominated for Best Poster Presentation at the at the 2002 International Society for Pharmacoeconomics and Outcomes Research Fifth Annual European Congress for the following presentation: Koopalum D, **Martin BC**. “Factors Influencing Inappropriate Antibiotic Prescribing for Children with Acute Bronchitis in Ambulatory Care Setting” Rotterdam, Netherlands, November 4, 2002 (*Value in Health* 2002; 5: 574-5)

Career Development Certificate of Recognition for greatly contributing to the career development of UGA students, September 1, 2002.

Named Chair of the International Society for Pharmacoeconomics and Outcomes Research Task Force on Retrospective Data Base Studies. 2002

Selected as Gold Review Panel for the Journal of Managed Care Pharmacy 2002-03

Named in Who’s Who in Medicine and Healthcare, 4th Edition.

Named in Who’s Who Executive and Professional Registry, 2003

Recipient of the 1996 American Association of Colleges of Pharmacy New Investigator Awards, \$9,964 for the research proposal entitled "Schizophrenia in the Medicaid Population: A Cost of Illness Study"

Finalist for the (1996) Third Annual National Institutes for Health Care Management Research Award. The paper entitled "The Impact of a Prescription Limit on Medicaid Recipients: Effects on Cost, Therapy, and Out-of-Pocket Expenditures" was one of five finalist selections from the United States among refereed publications in the areas of health policy.

Rho Chi Honor Society (member)

Licensure: Georgia Registered Pharmacist #016337

NIH era Commons ID: BCMARTIN

EDITORSHIP OR EDITORIAL BOARD MEMBER OF JOURNALS

EDITORIAL BOARD MEMBER

Current Research and Medical Opinion

Journal of Managed Care Pharmacy

Innovations in Pharmacy (Science Editorial Team Member)

JOURNAL REFEREE

JAMA

Pharmacoepidemiology and Drug Safety

(Rated as Among the best of all Reviewers)

PLOS ONE

Medical Care

Value in Health

Journal of Substance Use and Misuse

Journal of Managed Care Pharmacy

(Selected as Gold Review Panel)

Journal of Social and Administrative Pharmacy

Schizophrenia Bulletin

American Journal of Hospital Pharmacy

The Annals of Pharmacotherapy

Journal of Geriatric Drug Therapy

Clinical Therapeutics

Journal of Pharmaceutical Marketing and Management

Clinical Gastroenterology and Hepatology

GRANT REVIEW PANELS

2015 NIH Director's Early independence Award (DP5) Special Emphasis Panel/Scientific Review Group 2015 / 08 ZRG1 RPHB-W (53) R

2014 – 2015 TRI Pilot Study Section

2012 CDC - U01 Research to Prevent Prescription Drug Overdoses

2008-2012 Children's University Medical Group Grant (CUMG) Intramural Program

2011 American Association of Colleges of Pharmacy New Investigator Programs for Pharmacy Faculty, Social and Administrative Sciences Review Panel, Member

2008 Agency for Health Care Research and Quality (AHRQ): Special Emphasis panel, National Research Service Award Institutional Research Training Grant (T32), January 31 – February 1, 2008.

1997 - 1998 American Association of Colleges of Pharmacy New Investigator Programs for Pharmacy Faculty, Social and Administrative Sciences Review Panel, Member

1998 - 1999 American Association of Colleges of Pharmacy New Investigator Programs for Pharmacy Faculty, Social and Administrative Sciences Review Panel, Member

PUBLIC AND UNIVERSITY SERVICE

PUBLIC SERVICE

2017-present	The Great Arkansas River Cleanup – North Little Rock, Organizer for Rockwater Crew
2017-2020	Ouachita trail 50 mile endurance run, Aid Station Captain, Little Rock, AR
2015-2021	Diner Server, Bethlehem House, Conway, AR
2016	Baptist Medical Mission International, Pharmacist Volunteer on Peru Medical Mission.
2011 – Present	Arkansas Canoe Club Rescue Volunteer
2008	Red Cross Volunteer, Clinton Arkansas Tornado Disaster Relief

2007 – 2013	Arkansas Canoe Club Highway 65 Clean Up Crew
2006	Blankenship Conway Thanksgiving Dinner Delivery
2005	Faulkner County Rec. Department Assistant Soccer Coach
2005	Saint Josephs Hurricane Relief Supply Center, Volunteer
2004-present	International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Retrospective Database Development Task Force, Co-Chair
2004-present	International Society for Pharmacoeconomics and Outcomes Research (ISPOR), ISPOR Short Course Task Force, member
2003	Journal of Manage Care Pharmacy (JMCP) Award for Excellence for 2002, Judge
2002-2004	Mercy Clinic, Athens, GA Volunteer Pharmacist
2000-2003	International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Task force on Developing Guidelines for Retrospective Studies, Chair 2002
2001	Georgia State Science Fair, Judge
2001-present	University of Georgia Catholic Center, Special Projects Coordinator
2000-2004	Academy of Managed Care Pharmacy Faculty advisor for UGA student chapter
1992 - 2004	R.C. Wilson Pharmaceutical Association served as treasurer 1995-1997
1994 - present	Knights of Columbus (member)
1998	Oconee River Rendezvous Participant
1994 - 1996	Saint Joseph's School - (Science Fair Judge)
1989-1990	Athens Tutorial Center (Tutor)
1993 - present	Association for Health Services Research (member)

- 1992 - 1994 **American Public Health Association** (member)
- 1990 - present **American Association of Colleges of Pharmacy** (member, alternate
College or Pharmacy delegate 1993, 1995, 1997)

ADMINISTRATIVE and COMMITTEE SERVICES TO THE UNIVERSITY

- 2021-present Academic Senate, President Elect, President, Past President
2019-2021 Academic Senate, member
2019-2021 Chair, Constitutional Review Subcommittee
- 2021-present Targeted Review Subcommittee of the UAMS Pharmacy and Therapeutics
committee
- 2021-present College of Pharmacy Promotion and Tenure Committee, member
- 2020-2022 College of Pharmacy Scholastic Standing Committee, member
- 2020-2021 Deans ad-hoc Research Strategic Planning Committee, member
- 2021-present Parliamentarian UAMS College of Pharmacy
- 2020-2021 ACPE Self Study Committee, Co-Chair
- 2019-present University Research Committee, member
- 2019-2021 Director of Graduate Studies, UAMS College of Pharmacy
- 2019-2021 UAMS AR Clinical Data Repository Steering Committee, member
- 2019-present UAMS Translational Research Institute Team Science Committee, member
- 2017-2020 COP Student Research Committee, member
- 2018-2019 COP-Curriculum 2025, Integrated Disease State Blocks, Co-Chair
- 2016-2018 COP Pharmacy Practice Seminar Committee, Chair
- 2016-2019 UAMS Clinical Research Committee
- 2012-present Pharmaceutical Sciences Graduate Program Committee
- 2012-Present Pharmaceutical Evaluation and Policy Graduate Admissions
Committee

2010	ACPE Self Study Section Chair
2006-2009	Curriculum Committee, Graduate School
2008-2009	Promotion and Tenure Committee, College of Pharmacy
2005-2007	UAMS House of Delegates, member
2005-2007	UAMS Graduate Student Funding Committee, member
2002-2004	Committee for Graduate Faculty Review, member
2002-2004	College of Pharmacy Faculty Council, College wide representative
1999-2001	University Council, Executive Committee, member
1999-2001	University Council, Strategic Planning Committee, member
1998-2004	Department of Clinical and Administrative Sciences Graduate Education Committee, member
2002-2003	Parliamentarian, College of Pharmacy
1998-2000	College of Pharmacy Task Force on Strategic Planning, member
1997-1998	Faculty Affairs Committee of the University Council, CHAIR
1997-1998t	ACPE Self-Study Sub-Committee on Mission, Member
1999-2002 1995-1998	University Council, University of Georgia, member
1996- 1998	Faculty Affairs Committee of the University of Council, member
1996-2004	Computer Resources Committee, College of Pharmacy, member, Chair 1998-1999
1995	Annual Faculty Symposium sponsored by the Office of Vice President for Academic Affairs: Peer Review: The Scholarship of Teaching
1999-2002 1993-1995	Admissions Committee, College of Pharmacy, CHAIR 1994-1995, 2001-2002
1993	Task Force on Experiential Training for Doctor of Pharmacy Degree, College of Pharmacy, member

INTERNATIONAL, NATIONAL, REGIONAL, AND STATE PROFESSIONAL SERVICE

1. **Institute for Clinical and Economic Review (ICER), Midwest Comparative Effectiveness Public Advisory Council, voting member, 2021-present**
2. **ISPOR Student and Faculty Leadership Community, Co-Chair Elect of Member Engagement, 2023-present**
3. **ISPOR Short Course Programming Committee, member 2014-present**
4. **ISPOR Real World Evidence Transparency Initiative and Partnership, member 2019-2020**
5. **Arkansas Health Care Transparency Board, Governor Appointed Member, Member, 2016-present
Acting Chair, 2023**
6. **Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Board Member, 2016-2019**
7. **Program Committee Co-Chair, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) International Meeting. May 21-25, 2016**
8. **Reviewer, Academy of Managed Care Pharmacy (AMCP). Abstract Reviewer, 2014 – 2016.**
9. **Task Force Forum Presentation (ISPOR)**
Johnson M, Beger M, Mamdani M, Crown W, Martin BC, Cox E. “Design and Analysis of Non-Randomized Studies of Treatment Effects Using Secondary Data. May 6, 2008. Toronto, Canada.
10. **International Society for Pharmacoeconomics and Outcomes Research (ISPOR)**
Judge of Poster and Podium Presentations, 2002, 2004, 2005, 2010, 2013
Abstract Review Committee, 2001-2003, 2005-present
11. **Southern Pharmacy Administration Regional Meeting**
Abstract Review Chair, 2007
Planning Committee Member, 2007
12. **Conference Advisory Committee, Outcomes in Women’s Health Conference: Building Bridges Between Outcomes Research and Management of Women’s Health, April 16-18, 1998, Athens, GA.**
13. **Reviewer, American Pharmaceutical Association 1997 Annual Meeting**

14. **Presider**, session entitled: "Research Issues Associated with Measuring Pharmaceutical Care Outcomes" at the Pharmaceutical Care Outcomes Research Conference: Linking Research to Practice. September 27, 1996, Athens, GA
15. **Conference Advisory Committee**, Pharmaceutical Care Outcomes Research Conference: Linking Research to Practice. September 26-28, 1996, Athens, G
16. **North East Georgia SAS Users Group Steering Committee, member**

ROYALTIES - LICENSURES

1. An Opioid Risk Prediction Tool was licensed to TrestleTree LLC through Bioventures LLC, February 15, 2018. Role: Primary Inventor

CONSULTANTSHIPS

Development and Validation of a Clinical Decision Support Tool to Guide Oral Anticoagulant Prescribing in Patients with Atrial Fibrillation. eMax Health and Daiichi Sankyo

Bleeding and Recurrent Venous Thromboembolism Risk. eMax Health and Daiichi Sankyo

Costs of Pulmonary Hypertension to Managed Care. Bayer Healthcare Pharmaceuticals in collaboration with Qayyim Said.

Development and Validation of an Economic Model to assess the cost of diabetes care in Florida Medicaid, University of Florida.

Prescription validation survey of electronic prescription records. Express Scripts, Inc.

Determining the Net Cost of IBS. Novartis, Inc.

Validation of a Disease Specific Quality of Life Instrument. Glaxo Inc.

Analysis of Migraine Productivity Work Losses. Glaxo Inc.

Economic Analysis of PRAISE. Pfizer Inc.

Development and Editorial Assistance of an Outcomes Research Guide Manual. Pfizer, Inc.